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ABSTRACT 
 
Introduction  
 
Viral load is the most reliable indicator of poor adherence to anti-retroviral therapy (ART). 
However, this assay is difficult to implement in resource-limited settings due to financial and 
technical constraints.  
 Laboratory markers, combined with the patient’s demographic and clinical details, have been 
described as better proxies of adherence than the current self-reported adherence measures. 
However, the real diagnostic value of these biomarkers remains unknown. Therefore, the aim 
of this study was to assess the usefulness of a composite marker to identify poor adherence to 
ART defined as a detectable plasma viral load in HIV-positive patients on first-line regimen at 
Themba Lethu Clinic (TLC) in Johannesburg, South Africa 
 
Materials and Methods: 
This study was retrospective cohort analysis of data collected on HIV-positive ART naïve 
adults initiating first line antiretroviral regimen at TLC following the 2010 South African 
antiretroviral treatment guidelines. The data collection was carried out as part of the low-cost 
monitoring (LCM) study at Themba Lethu Clinic in Johannesburg from February 2012 to 2014. 
The LCM cohort which aims to look at low cost monitoring of HIV treatment in resource 
limited settings was initiated in 2009 in Johannesburg, South Africa. The study or treatment 
outcome was failure to suppress viral load (VL ≥ 400 copies/ml) at 6 and at 12 months. 
Adherence to antiretroviral treatment was assessed using four (4) self-reported adherence 
(SRA) measures namely: a self-reporting questionnaire, a Visual Analogue Scale (VAS), a pill 
identification test (PIT) and the Simplified Medication Adherence Questionnaire (SMAQ). The 
result of each self-reported measure was classified as either positive or negative given a 
conventional threshold. In our study three (3) self-reported adherence (SRA) measures were 
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combined into a multi-method approach tool which included self-reports combined with VAS 
and the pill identification test (PIT). 
Continuous variables were summarized by median with interquartile range. Categorical 
variables were summarized by giving their frequencies. To compare continuous variables, we 
used an unpaired t-test if the variable was normally distributed. When continuous variables 
were compared from baseline to the previous 6 months, a paired t-test was done. In the case of 
skewed distribution, we used a non-parametric variant of the t-test such as the Mann-Whitney 
U-test. To compare categorical variables, we used cross-tables with corresponding chi-square 
test or Fisher exact test.  
A Modified Poisson Generalized Linear Model (GLM) with robust variance was used to 
estimate adjusted relative risks (aRR) of failing to suppress viral load at 6 and at 12 months 
adjusting for age age, gender, self-reported adherence measures, changes in laboratory markers 
and missed appointments at 6 and 12 months after ART initiation. As there was missing values 
in the covariatess and the outcome, we performed a multiple imputation technique under 
missing at random (MAR) assumption in order to compare the robustness of the estimations 
between the complete case analysis and the imputation model under MAR after imputing 
missing values. with the imputed dataset.  
Additionally, we calculated the sensitivity, specificity, positive predictive value (PPV) and 
negative predictive value (NPV) for each self-reported adherence measure using viral load as 
the reference standard. Thus, we derived two diagnostic risk scores from rounding and adding 
together the adjusted regression coefficients used to estimate adjusted relative risk and 
following the Spiegelhalter and Knill-Jones approach, at 6 and at 12 months. The Receiver 
Operating characteristic (ROC) curves were computed to see the overall discriminative value 
of each continuous risk score. To assess the clinical usefulness of the continuous riskscores we 
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dichotomized them from 2 ≥ vs < 1 to 5 ≥ vs < 5 and calculated the sensitivity (Se), specificity 
(Sp), positive predictive value (PPV) and negative predictive value (NPV) at each cut-off, 
taking detectable viral load as a gold standard.  
Results: There were 353 HIV-positive patients initiated on first line ART at TLC for the LCM 
cohort study. Of these, 80.7% did not suppress viral load after 6 months while 30.1% did not 
suppress viral load at 12 months. The proportion of patients classified as being highly adherent 
was 86.7% but this proportion decreased to 60% at 12 months.   By 6 months, after adjusting 
for gender and age, the variables that were significantly associated with detectable viral load 
included: having missed at least two ARV visits by ≥ 7 days (aRR: 2.35 95% CI: 1.08 -5.11); 
platelet count < 150 cells/mm3 (aRR: 2.73 95% CI: 1.04 -7.18) and VAS ≤ 95% (aRR: 1.65. 
95% CI: 1.01-2.71). At 12 months, the estimates showed a positive relationship only with age 
group and unemployment. There were no similarities in the results found using complete case 
analysis and analysis with imputed datasets. However, the largest standard errors were obtained 
from the complete case analysis.   
At 6 months, the AUC ROC curve was calculated as 0.63 (95% CI, 0.53 - 0.72) while, for the 
visual analogue scale, the AUC decreased to 0.55 (95% CI, 0.49 - 0.62); for the Simplified 
Medication Adherence Questionnaire (SMAQ), the AUC decreased to 0.52 (95%CI, 0.45 - 
0.60), while for the multi-method approach, it decreased to 0.53 (95% CI, 0.46 - 0.58). The 
optimal diagnostic accuracy was obtained with the score 5 (≥5 vs <5 Se: 64% and a Sp: 50.0%) 
followed by a risk score of 4 (Se of 76.0%, Sp of 34.7%). At 12 months, the AUC of the 
diagnostic risk score was calculated as 0.44 (95%CI, 0.40 - 0.60) while for the three self-
reported adherence methods, it decreased to 0.48 (95% CI, 0.40 - 0.60), 0.51 (95%CI, 0.40 - 
0.60) and 0.50 (95%CI, 0.41 - 0.59) respectively for the visual analogue scale, the SMAQ and 
the multi-method approach method respectively. 
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Conclusion. This study shows that after ART initiation, the 6-month’s adherence can be better 
diagnosed using laboratory markers combined with patient’s information and traditional self-
reported adherence measures at Themba Lethu Clinic. The advantage of this proposed method 
is that it is based on routine and accessible informations collected during HIV-positive patient 
visits, thus incurring no additional cost for its implementation. An external validation of this 
diagnostic risk score is needed for its translation into clinical practice in resource-limited 
settings. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
viii 
 
ACKNOWLEDGEMENTS 
 
I would like to thank the West African Platform for HIV Intervention Research (WAPHIR 
Network) for their financial support during my studies at the University of the Witwatersrand. 
I would like to thank and express my sincere gratitude to my supervisors, Professor Charles 
Chasela and Dr Denise Evans for their constant support, guidance and advices during the 
research and writing process. Their expertise and comprehension were invaluable for this 
present research report. 
I would like to thank all the lecturers and administrative staff from the School of Public Health 
(University of the Witwatersrand). Thank you to the Health Economics and Epidemiology 
Research Office (HE²R0) for allowing me to access their data and for their support during the 
preparation of this report.  
This research report would not have been possible without the support from the NIH under the 
NIH/CFAR Creative and Novel Ideas in HIV Research CNIHR: low cost monitoring of HIV 
in resource-limited settings UAB CFAR grant number: P30AI027767. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
ix 
 
TABLE OF CONTENT 
DECLARATION ___________________________________________________________ i 
DEDICATION ____________________________________________________________ iii 
ABSTRACT ______________________________________________________________ iv 
ACKNOWLEDGEMENTS _________________________________________________ viii 
TABLE OF CONTENT _____________________________________________________ ix 
LIST OF FIGURES ________________________________________________________ xii 
LIST OF TABLES ________________________________________________________ xiii 
NOMENCLATURE ________________________________________________________ xv 
CHAPTER ONE: INTRODUCTION ,LITERATURE REVIEW,  AIMS AND OBJECTIVES ___ 1 
1.1 Background ....................................................................................................................... 1 
1.2 Problem statement ...................................................................................................... 4 
1.3 Justification for the study ........................................................................................... 6 
1.4 Literature review ........................................................................................................ 6 
1.5 Study aim and objectives ......................................................................................... 11 
1.5.1 Research question _____________________________________________________ 11 
1.5.2 Aim of the study_______________________________________________________ 11 
1.5.3 Study objectives _______________________________________________________ 11 
CHAPTER TWO - MATERIALS AND METHODS ______________________________ 13 
2.1 Introduction ........................................................................................................................ 13 
2.2 Study design ....................................................................................................................... 13 
2.3 Study Setting ...................................................................................................................... 14 
2.4 Study population ................................................................................................................ 16 
2.4.1 Inclusion criteria ______________________________________________________ 16 
2.4.2 Exclusion criteria ______________________________________________________ 16 
2.5 Study sample ...................................................................................................................... 17 
2.6 Data sources and measurement .......................................................................................... 17 
2.6.1 Data sources __________________________________________________________ 17 
2.6.2 Definition and measurement of outcomes and exposures _______________________ 19 
2.6.3 Data management______________________________________________________ 25 
2.7 Statistical methods ............................................................................................................. 27 
2.7.1 Exploratory Analysis ___________________________________________________ 27 
2.7.2 Descriptive Analysis ___________________________________________________ 28 
2.7.3 Inferential Analysis ____________________________________________________ 28 
2.7.4 Elaboration of the diagnostic prediction model at 6 and 12 months _______________ 31 
2.7.5 Sensitivity Analysis ____________________________________________________ 31 
2.8 Ethics clearance ................................................................................................................. 33 
3.1 Organization of the study cohort and total number of participants ................................... 34 
3.2 Baseline demographic characteristics ................................................................................ 35 
   
x 
 
3.3 Baseline clinical characteristics at ART initiation ............................................................. 36 
3.5 Comparison of demographic and clinical characteristics of 290 HIV-patients with 
detectable and undetectable viral load at 12 months ............................................................... 42 
3.6 Description of the missing values in the LCM dataset ...................................................... 43 
- Missing values at 6 months _____________________________________________ 44 
- Missing values at 12 months ____________________________________________ 44 
3.7 Complete case analysis ...................................................................................................... 46 
3.7.1 Self-reported adherence at 6 and 12 months of ART therapy ____________________ 47 
3.7.2 Comparison of the result of self-reported between patients between with detectable viral 
load and patients with undetectable viral load. ____________________________________ 49 
3.7.3 Comparison of the result of self-reported adherence between patients with and with 
undetectable viral load at 6 months. ____________________________________________ 49 
3.7.4 Comparison of the result of self-reported adherence between patients with detectable 
and patients with undetectable viral load at 12 months. _____________________________ 49 
3.7.5 Crude and adjusted predictors of detectable viral load (n=163) at 6 months after ART 
initiation, using modified Poisson regression analysis. _____________________________ 50 
3.7.6 Crude and adjusted predictors of detectable viral load (n=142) at 12 months after ART 
initiation, using modified Poisson regression analysis ______________________________ 53 
3.7.7 Sensitivity, specificity, PPV and NPV of the self-reported measures of predicting 
adherence to ART compared to reference standards of viral load Erreur ! Signet non défini. 
3.7.8 Comparison of changes in laboratory markers between patients with and without 
detectable plasma viral load __________________________________________________ 59 
- Comparison of changes in laboratory markers between patients with and without 
detectable plasma viral load at 12 months _______________________________________ 61 
3.7.9 Sensitivity, specificity, PPV and NPV of the laboratory markers for predicting 
adherence to ART compared to reference standard of viral load ______________________ 61 
3.7.10 Risk scoring from the multivariate model for predicting a detectable viral load at 6 and 
12 months ________________________________________________________________ 64 
3.7.11 Diagnostic accuracy of the risk scoring and the self-reported methods to detect viral 
load in patients at the Themba Lethu Clinic ______________________________________ 64 
3.7.12 Sensitivity, specificity, PPV and NPV of the diagnostic risk score at different cut-off 
values compared to reference standard of viral load _______________________________ 67 
3.7.13 Clinical usefulness of the diagnostic risk score in practice at 6 months ___________ 70 
3.8 Sensitivity Analysis ........................................................................................................... 74 
3.8.1 Relation between missingness of the demographic characteristics and the measured 
viral load at 6 and 12 months after ART initiation _________________________________ 74 
3.8.2 Relation between missingness of clinical characteristics and detectable at viral load at 6 
months ___________________________________________________________________ 76 
3.8.3 Relation between missingness of clinical characteristics and a detectable viral load at 12 
months ___________________________________________________________________ 76 
3.8.5 Comparison of complete case analysis and imputed results _____________________ 79 
CHAPTER FOUR- DISCUSSION _____________________________________________ 82 
4.1 Introduction ........................................................................................................................ 82 
4.2 Summary of results ............................................................................................................ 82 
4.3 Viral load suppression during the first 6 and 12 months on ART ..................................... 84 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
   
xi 
 
4.4 Laboratory markers changes and viral load response ........................................................ 85 
4.6 Self-reported adherence (SRA) and viral load response .................................................... 91 
4.7 Diagnostic risk score and viral load ................................................................................... 96 
4.8 Plausible reasons for missingness and impact of the missing data .................................. 101 
4.9 Limitations of the study ................................................................................................... 101 
CHAPTER FIVE - CONCLUSION AND  RECOMMENDATIONS _________________ 103 
5.1 Introduction ...................................................................................................................... 103 
5.2 Conclusion ....................................................................................................................... 103 
5.3 Recommendations ............................................................................................................ 106 
 
    6. REFERENCES ……………………………………………………………………… .     121 
APPENDICES…………………………………………………………………………   …128 
7.1 Appendix A: Plagiarism declaration 
7.2 Appendix B: Clearance certificate  
7.3 Appendix C: Permission to use the LCM study database 
7.4 Appendix D: Simplified Medication Adherence Questionnaire (SMAQ) 
7.5 Appendix E: Characteristics of patients in the Themba Lethu Clinical HIV Cohort and the 
LCM study  
          
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
xii 
 
LIST OF FIGURES 
 
Figure 1 TRIPOD schematic representation of diagnostic study: (Collins et al, 2015). ......... 14 
Figure 3 ROC curve for the calculated diagnostic risk score, the VAS, the SMAQ and the 
multiple approach method at 6 months. .................................................................... 66 
Figure 4 ROC curve for the calculated diagnostic risk score, the VAS, the SMAQ and the 
multiple approach method at 12 months. .................................................................. 66 
Figure 5 Clinical usefulness of the diagnostic risk score in practice at 6 months with a cut-off 
value of 5. (TN True negative; TP True positive; FN False negative; FP False 
positive)..................................................................................................................... 72 
Figure 6 Clinical usefulness of the diagnostic risk score in practice at 6 months with a cut-off 
value of 4. (TN True negative; TP True positive; FN False negative; FP False 
positive)..................................................................................................................... 73 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
xiii 
 
LIST OF TABLES 
 
Table 1  Data Source of different informations collected during the study. ........................... 18 
Table 2  Summary of different cut-off values used by type of laboratory markers. ............... 24 
Table 3  Baseline demographic characteristics of 353 ART- naive patients. ......................... 37 
Table 4  Baseline Clinical characteristics at ART initiation. .................................................. 38 
Table 5  Comparison of demographic and Clinical characteristics of 296 HIV-infected 
patients with detectable viral load at 6 months. ........................................................ 41 
Table 6  Comparison of demographic and clinical characteristics of 290 HIV-infected 
patients with detectable and undetectable viral load at 12 months. .......................... 43 
Table 7  Description of the missing values in the LCM dataset at 6 and at 12 months .......... 45 
Table 8  Self-reported adherence at 6 and at 12 months on ART. .......................................... 48 
Table 10 Crude and adjusted predictors of detectable viral load (n=142) at 12 months after 
ART initiation. .......................................................................................................... 54 
Table 11 Changes in laboratory markers in patients and detectable viral load. ...................... 60 
Table 12 Sensitivity, Specificity, PPV and NPV of the changes in laboratory markers for 
predicting adherence to ART compared with viral load. .......................................... 63 
Table 14 Diagnostic accuracy of the risk score at different cut-off points at 6 months after 
ART initiation. .......................................................................................................... 69 
Table 15 Association between viral load detectable at 6 and at 12 months and missing values 
in baseline demographic characteristics.................................................................... 75 
Table 16 Relation between missingness of clinical and laboratory markers and detectable 
viral load at 6 and 12 months. ................................................................................... 77 
Table 17 Results of the multiple imputation for estimation of the predictors of ART at 6 
months after ART initiation. ..................................................................................... 80 
   
xiv 
 
Table 18 Results of the multiple imputation for estimation of the predictors of ART at 12 
months after ART initiation. ..................................................................................... 81 
Table 20 Sensitivities and specificities of different CPS in the literature. ............................ 100 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
xv 
 
LIST OF ACRONYMS AND ABBREVIATIONS 
ACTG AIDS Clinical Trials Group    
AUC                         Area Under Curve    
3TC Lamivudine 
   
                        
AIDS 
Acquired Immunodeficiency Syndrome 
 
ART  Antiretroviral Therapy 
  
ARV  Antiretroviral 
  
CASI  Computer-Assisted Self-Interviewing 
 
CD4  Cluster of Differentiation 
  
CDC Center for Diseases Control and Prevention 
CPS Clinical Prediction Score    
d4T Stavudine 
   
DOH Department of Health 
 
EFV Efavirenz 
   
EVP 
FN                            
FP   
FTC    
Events Per Variable 
False Negative 
False Positive 
 Emtricitabine 
HE²RO Health Economics and Epidemiology Research Office 
HIV Human Immunodeficiency Virus 
 
HSRC Human Sciences Research Council    
LPV Lopinavir 
   
HSRC                      Human Sciences Research Council    
MAR  Missing at Random 
  
MCAR  Missing Completely at Random 
 
MCV Mean Corpuscular Volume  
MEMS                
MNAR    
Medication Event Monitoring System 
Missing Not at Random 
 
NDOH National Department of Health 
 
NGO                      Non-Governmental Organization 
NNRTI  Non-Nucleoside Reverse Transcriptase 
NPV Negative Predictive Value  
 
   
xvi 
 
NRTI  Nucleoside Reverse Transcriptase 
 
NVP Nevirapine 
   
PI  Protease Inhibitor 
  
PIT  Pill Identification Test 
  
PPV  Positive Predictive Value 
  
ROC  Receiver Operating Characteristics 
 
SMAQ  Simplified Medication Adherence Questionnaire  
SRA Self-Reported Adherence 
  
TDF Tenofovir Fumarate 
   
TDM  Therapeutic Drug Monitoring 
 
TLC                     Themba Lethu Clinic   
TN True Negative   
TP True Positive   
USAID United States Agency for International Development 
  
VAS  Visual Analogue Scale 
  
VL Viral Load 
   
WHO World Health Organization 
 
 CHAPTER ONE: INTRODUCTION LITERATURE REVIEW, AIMS AND OBJECTIVES 
 
In this chapter, background is provided including the importance of adherence to antiretroviral 
treatment and its monitoring. In addition, the problem statement and reasons for this research 
are also explained and the results of literature review are given. The chapter ends with a 
statement of the research question and a description of the aim and objectives of the study. 
 
1.1 Background    
The human immunodeficiency virus (HIV) epidemic remains a major public health problem in 
the world. In 2012, 36 million people were living with HIV and 2.3 million individuals were 
newly infected globally (UNAIDS, 2013). Sub-Saharan Africa bears the burden of the 
epidemic with 25 million people living with HIV and 1.2 million deaths due to Acquired 
Immunodeficiency Syndrome (AIDS) in 2012 (UNAIDS, 2013). 
The scaling-up of antiretroviral therapy (ART) program has reduced the impact of the 
HIV/AIDS epidemic. Around the world, antiretroviral drugs have reduced mortality and 
increased life expectancy among HIV-positive  persons (UNAIDS, 2013) (Kirk, 2003). In 
2012, more than 9 million people were on ART in low and middle income countries (UNAIDS, 
2013). This number represented 65% of the global target of 15 million  people on ARV before 
the 2015 deadline (UNAIDS, 2013)  
In South Africa, the estimated prevalence of  HIV in the general population is 12%, 
representing 6.4 million people living with HIV and of which 31.2% were on ART treatment 
(HSRC, 2012).The distribution of the HIV infection differs by gender, age and geographic area. 
The highest prevalence is found in KwaZulu Natal with 17% while, in Gauteng province the 
HIV prevalence is around 12.5%  (HSRC, 2012).   
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Since 2004, South Africa has made comprehensive efforts toward achieving free and greater 
access to antiretroviral treatment in the world. Currently, over 2 million HIV-positive people 
are receiving antiretroviral therapy in line with  the South African  ART treatment guidelines  
in 3,400 facilities across the country (UNAIDS, 2014). In 2014, the coverage of the national 
ART programme was estimated to be around 50% in South Africa (UNAIDS, 2014). 
In South Africa, the main goal of the ART programme is to save life, achieve the best outcome 
in the most cost-efficient manner, decentralize service delivery in public health facilities and 
mitigate the impact of the HIV/AIDS epidemic (DOH, 2013). Based on World Health 
Organization (WHO) recommendations, ART eligibility criteria for HIV adult patients 
initiating in South Africa requires the following conditions: being either an HIV-positive 
patient with a CD4 count less than 350 cells/mm3, or a patient co-infected with tuberculosis or 
an HIV-positive woman who is pregnant or breastfeeding, regardless of CD4 count level. The 
same rule applies to HIV-positive patients with opportunistic infections or at stage 3 or 4 of 
WHO stage classification. 
At ART initiation, first-line treatment consists of two nucleosides reverse transcriptase 
inhibitors (NRTIs) with one non-nucleoside reverse transcriptase inhibitor (NNRTI). 
Consecutively, different combinations or substitutions involving NNRTI and NRTI can be 
made when drug toxicity and interactions occur (WHO, 2012). However, the switch to second 
line ART is only recommended when the plasma HIV-RNA is greater than 1,000 copies/ml 
during two consecutive measurements made within 2 months. Second-line ARTs generally 
combine two nucleoside reverse transcriptase inhibitors (NRTIs) with a protease inhibitor (PI) 
(WHO, 2010) (DOH, 2013). 
The number of persons on ART is still increasing the major reason being that the national ART 
program has extended over a decade and the treatment is now available in many urban and 
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rural areas. Standard ART regimen is a combination of antiretroviral drugs that need to be taken 
correctly during the one’s entire lifetime to suppress the HIV virus. 
Because of this increase in the number of persons initiated on ART, monitoring adherence to 
is now a key strategy for the success of the ART programme. Poor adherence leads to treatment 
failure, higher risk of mortality amongst HIV-infected patients and the need to treat patients 
with costlier second and third-line ART, a situation that reduces the gains from several years 
of therapy (WHO, 2012). WHO defines treatment adherence as “the extent to which a person’s 
behavior – taking medications, following a diet and/or executing lifestyle changes – 
corresponds with agreed recommendations from a health care provider” (WHO, 2003). For 
ART  drugs,  at least 90% compliance is required for virologic suppression  among HIV-
positive patients (WHO, 2003). In South Africa,  several adherence assessment methods (self-
report, visual analogue scale, pill-count and pill-identification, pharmacy records, and the 
Simplified Medication Adherence Questionnaire) are currently used  in clinical practice (Berg 
& Arnsten, 2006). However, the performance of these methods is limited by their poor 
sensitivity and specificity when compared to viral load, which is considered to be the gold 
standard method (Berg & Arnsten, 2006). In addition, these methods tend to over-estimate 
adherence due to many factors such as recall-bias and lack of standardization (Bartley et al, 
2013). Since the viral load is not available everywhere, there is an urgent need to invest in 
alternative and low-cost methods that could be used to assess and monitor adherence to ART 
among HIV-positive patients accurately. 
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1.2 Problem statement  
 
Adherence to an ART regimen is critical for the success of antiretroviral therapy at individual 
and community level. Many studies have shown that a low level of adherence is the most well-
known reason associated with drug resistance, treatment failure and mortality in HIV-positive 
patients. Conversely, the benefits  of high adherence  include suppression of viral replication, 
high level of CD4 cells, prevention of drug resistance, rapid immune reconstitution and slow 
disease progression (Berg & Arnsten, 2006; de Olalla et al, 2002). It has been shown that, at 
community level, good adherence improves the long-term impact of ART programmes by 
increasing life-expectancy among HIV-infected people  and reducing HIV-transmission  
(Mannheimer et al, 2006; Cohen et al, 2011). A good adherence level requires  the patient to 
take at least 95% of the medication prescribed and  at the correct time (WHO, 2003). Without 
accurate monitoring, patients with poor adherence will continue to have high viral loads, 
treatment failure and drug resistance. As a result, in the long term,  non-adherent HIV-positive 
patients on tri-therapy are four  times more likely to die than  adherent patients initiated  on the 
same therapy (de Olalla et al, 2002). 
While adherence to ART is critical, there is still no consensus on the most suitable method to 
monitor and assess it accurately. In developed countries, the viral load assay is routinely used 
to monitor adherence in patients on ART. However, in resource-limited settings this technique 
is extremely costly ($15-$150 per test) and cannot be performed routinely (Colebunders et al, 
2006). Moreover, viral load assays require well equipped laboratories and the ability for the 
health system to provide highly trained staff. This situation is not the case everywhere in South 
Africa where only tertiary reference laboratories are able to perform viral load assays (Stevens 
& Marshall, 2010). Due to  technical and financial constraints, primary health care facilities 
and secondary facilities located in rural areas, which account for more than 75% of the health 
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system, are not able to perform HIV-viral load assays routinely (Stevens & Marshall, 2010). 
As an alternative to viral load assays, the adherence assessment methods currently used in 
clinical settings include self-reporting, visual analogue scale, pill count and pharmacy refill 
records. However, there is evidence of poor sensitivity and a risk of overestimation when these 
methods are used to assess and monitor adherence among patients on ART (Bartley et al,2013).  
In an evaluation study in South Africa using viral load as a gold standard, the sensitivity and 
specificity of the visual analogue scale for different cut-offs were 66%, 46% and 29% 
respectively (Meyer et al,2012). For adherence levels assessed with pharmacy-refill data, the 
sensitivity was 55%, 15%, and 6% (Meyer al. 2012). There is also evidence that self – reported 
methods are susceptible to recall bias when applied over a long period (Bartley et al‘ 2013).  
While most of the traditional indirect methods fail to assess adherence to ART accurately, there 
is also increasing evidence that routine laboratory biomarkers could provide an alternative. 
Laboratory markers collected routinely have the potential to assess the virologic failure and 
adherence to ART accurately (Van Griensven et al,2014; Robbins et al,2010). Studies have 
shown that individual markers such haemoglobin , mean corpuscular volume, total lymphocyte 
count, serum lactate, CD-38, and bilirubin can be used as an alternative to viral load assays to 
predict adherence (Ross-Degnan et al,2010; Steele et al,2002). Furthermore, the main 
advantage of these routine biomarkers over the traditional methods is that they are easy to 
collect and are available in routine clinical care. However, despite their potential, many of these 
biomarkers have been evaluated in the context of retrospective studies. Although they are 
simple and feasible, predictive models based on retrospective datasets has several limitations. 
First, they have missing values and may lead to selection bias that would affect their validity. 
A second limitation  is the poor generalizability of the results (Steyerberg et al, 2013). Finally, 
the added value of each biomarker when they are combined or mixed with other indirect 
methods is still unknown. Since a prospective design is the best indicated method, the 
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diagnostic value of these promising biomarkers need to be assessed using a study with a 
prospective design.  
1.3 Justification for the study  
Viral load is known as the gold standard to assess adherence in patients on ART. However, this 
technique is unavailable in many areas due to financial and technical constraints. Despite their 
wide use, the validity of the current indirect methods based on questionnaires and pharmacy 
records remains limited. To assess the usefulness of laboratory markers as alternative methods, 
previous findings from retrospective datasets need to be confirmed with a prospective study. A 
prospective evaluation of relevant biomarkers will enable us to define an accurate and low-cost 
method for medication adherence assessment. 
In resource-limited settings where viral load is often unavailable, such a new method based on 
routine data could be useful for clinicians to effectively monitor adherence to ART and address 
the issue of treatment failure among HIV-positive patients in good time. Furthermore, at the 
national level, the availability of a simplified, low-cost performant tool will reduce the use of 
viral load assays; hence improve the sustainability of the national ART program. 
1.4 Literature review  
The positive impact of highly antiretroviral treatment in reducing mortality and morbidity 
related to AIDS has been demonstrated and recognized in observational and experimental 
studies. Research findings have demonstrated the effectiveness of early combination of 
antiretroviral drugs to prevent the transmission of  HIV-1 virus (Cohen et al, 2011). 
Adherence to ARV treatment, detectable viral load, and treatment failure and drug resistance 
are closely linked. Poor adherence to highly active ART regimen is a major  cause of HIV drug 
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resistance and  non-adherent patients on triple therapy are  about four  times more likely to die 
than adherent patients on the same therapy (de Olalla et al, 2002). 
 Moreover, the long term benefit of ART is lowered when the patient is non-adherent  
(Mcmahon et al, 2013). Many factors can negatively affect the change in viral load among 
patients on first line therapy. These include ART regimen, adherence to treatment, existence of 
drug resistance and drug metabolism, genetic differences and clinical stage at the beginning of 
the treatment (Tran et al, 2014). However, studies  have shown that the factor  most  related  to 
viral load change and HIV/AIDS progression is  adherence to therapy (Luebbert et al, 2012).  
The WHO public health strategy recommends a combination of CD4 count with clinical criteria 
as an alternative method to assess viral load suppression in HIV-positive patients (Gilks et al, 
2006). Although not specifically designed to target a single elevated viral load but for assessing 
virologic failure, defined as two successive measures of viral load greater than 400 copies/ml, 
the capacity of this strategy to predict virologic failure is poor (Robbins et al, 2010). In South 
Africa, an evaluation study of the WHO criteria among adults revealed that the CD4 count 
criteria had a sensitivity of 21% and specificity of 58% in detecting virologic failure and 
clinical criteria had a sensitivity of 15.2% and specificity of 88.1%. The positive predictive 
value of the CD4 count and the clinical criteria in detecting virologic failure was 36.8% and 
12.8 % respectively (Mee et al, 2008). Another challenge for implementing routine viral load 
measurement is related to financial cost and technical constraints. While the viral load 
measurement as a method for monitoring and addressing the issue of adherence appears to be 
realistic in developed countries, in resource-limited settings the absence of well-equipped 
laboratories and financial constraints limit its general use in the public health sector, 
specifically in rural areas (Colebunders et al, 2006). Instead of viral load, many alternative 
methods for measuring adherence directly are also available and currently used in routine 
clinical care. These include self-reporting, the Visual Analogue Scale (VAS), the pill count 
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method, the pharmacy refill records, and Simplified Medication Adherence Questionnaire. 
While these methods are largely used by the clinicians, they are limited by their lack of 
sensitivity, specifically in situations of poor adherence (Berg & Arnsten, 2006). Moreover, they 
also  give poor results due to many biases when applied over a long  period  (Bartley et al, 
2013). Additionally, there is evidence that self-reported adherence measures such as VAS may 
overestimate adherence, especially when questionnaires are administered by health 
professionals (Giordano et al, 2004). Pill identification tests involve inviting patients to identify 
the pills in the antiretroviral regimen. One of the inconveniences of this method is related to 
the loss of sensitivity in treatment experienced patients and for not being a sensitive marker of 
actual pill intake (Berg & Arnsten, 2006)  
Recently, the use of electronic devices for monitoring adherence to ART has been advocated 
based on research findings in developed countries .The Medication Event Monitoring System 
(MEMS) (Berg & Arnsten, 2006; Ailinger et al,2008) is an electronic device included with pill 
containers and it records the removal of the cap of the counter by a patient or another person. 
This method has been used in the industry and is reliable for recording dose histories. It 
represents a good proxy for the removal of pills and then to adherence. However, difficulties 
associated with routine use of MEMS are related to the fact that the patient can open the bottle 
and not necessarily take the pil. Additionally, the cost associated with this method and its use  
is high  (Berg & Arnsten, 2006). 
The best method for assessing adherence to ART should be low cost, brief and non-intrusive 
so that it could be used many times over the course of the treatment.  In addition, it should be 
reliable and acceptable to the HIV-positive patient while also being sensitive enough to 
measure change (Evans & Fox, 2013). Estimation methods based on the combination of routine 
biomarkers with information on adherence to ART and clinical stage of the patients better 
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predict detectable viral load when compared with the traditional methods based on 
questionnaires and self-reporting (Evans & Fox, 2013).Moreover, results from observational 
studies have documented the changes in certain immunological and hematological biomarker 
levels and their interrelationship with  adherence  and the treatment outcome (Cosby, 2007).The 
changes in platelet count, total lymphocytes and their correlation with the viral load have been 
documented amongst HIV positive adults adults on ART treatment (Cosby et al, 2007; Denue 
et al, 2013).  
Additionally,many studies suggest  that changes in mean corpuscular volume for HIV-positive 
patients taking either Zidovudine (AZT) or Stavudine (d4T) may be a useful surrogate marker 
for adherence to ART (Steele et al, 2002; Meriki et al, 2014). There is increasing evidence from 
retrospective and observational studies that MCV is one of the hematologic parameters 
proposed as an early clinical indicator of ART adherence (Mugisha et al, 2012; Kufel et al, 
2016).  
In a retrospective study, Romanelli et al, (2002) showed that the incidence of macrocytosis is 
significantly different between adherent and non-adherent patients (78% vs 32.6% p < 0.001). 
This study showed a clear link between the rise of MCV levels and strict adherence to 
Zidovudine after ART initiation. A rise in MCV is also observed in patients on Stavudine, 
another thymidine analogue. In certain settings, MCV has been used to assess adherence to 
ART in HIV-positive patients (Romanelli et al, 2002; Segeral et al, 2010). However, other 
recent studies (Mugisha et al, 2012; Kufel et al, 2016) have claimed that the long-term effect 
of Zidovudine or Stavudine based regimens on the MCV remain unclear (Mugisha et al, 2012).  
Like mean corpuscular volume, the platelet count is also known as a potential biomarker of 
poor adherence to ART. More recently, Zetterberg et al (2013) have shown that interrupting 
ART is associated with an increased risk of thrombocytopenia.  
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Additionally, however, data from cohort studies has shown that the reintroduction of ART 
therapy reverses the thrombocytopenia. However, the cut-off level at which the platelet count 
can be used as biomarker of ART adherence still remains unclear (Meriki et al, 2014). 
In a retrospective study, Petersen et al, (2005) used 134 HIV-positive patients to assess the 
usefulness of bilirubin as a potential biomarker of poor adherence to ART in HIV patients on 
Atazanavir-based regimens. They found that an increase in bilirubin of more than 0.4 mg/dl 
correctly classified 81% of patients as having successful ART adherence and treatment 
response. In another experimental study, Mugo et al (2013) showed that asymptomatic 
hyperlactatemia (serum lactate concentration ≥ 2 mmol/L)  was associated with being treated 
with NRTI/PI and having an undetectable viral load regardless of treatment regimen. Except 
for patients receiving Zidovudine, studies have shown that, after ART initiation, hemoglobin 
levels increase amongst HIV-positive individuals with a good adherence level. In studies 
conducted in Europe (Benito et al, 2004; Ondoa, 2005), a fall in hemoglobin levels and total 
lymphocytes count below baseline levels after 6 months following ART initiation better 
predicted the absence of viral load suppression among patients. Studies also revealed that the 
expression of CD8+CD38+T cell count is an independent marker of plasma viral load in infants 
treated with first-line ART (Benito et al, 2004; Ondoa, 2005). Studies in Europe and West 
Africa (Ondoa. 2005; Colebunders et al, 2006; Schreibman & Friedland, 2004; Cosby, 2007) 
showed that, among positive patients receiving ART, the proportions of CD8+Tcell expressing 
the activation marker of CD38 was correlated with treatment outcome and virological failure 
(Ondoa. 2005). 
Furthermore, immunological and clinical information on missing visits have been previously 
identified as predictors of adherence to ART treatment in a large retrospective cohort patient 
analysis in South Africa. This study that used retrospective datasets from South Africa 
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identified that the change in MCV at 6 months of < 14.5 fL , the number of missed visits (days) 
and regimen dosing were potential biomarkers of adherence  (Brennan et al, 2010). Despite the 
association between the changes and these biomarkers on the one hand, and their potential 
usefulness on the other, many of these studies have used a retrospective design. Therefore, the 
real diagnostic accuracy of these potential biomarkers needs to be confirmed within studies 
with a prospective design.  
 
1.5 Study aim and objectives  
 
1.5.1 Research question  
What are the most significant markers of medication adherence among ART naïve patients on 
a first line regimen?   
1.5.2 Aim of the study  
The aim of the study was to determine the usefulness of a composite marker to identify poor 
adherence to ART, defined as VL ≥ 400 copies/ml in patients on first-line ART at Themba 
Lethu Clinic (TLC) in Johannesburg, South Africa. 
1.5.3 Study Objectives 
i. To compare the demographic and clinical characteristics of patients on first line 
antiretroviral treatment with a detectable viral load (VL ≥ 400 copies /ml) with those 
with a viral load < 400 copies/ml at 6 and 12 months after ART initiation. 
ii. To determine the association between (i) self-reported adherence, (ii) CD4 response, 
(iii) MCV response, (iv) missed appointment, (v) new condition symptom, (iv) MPR or 
(vii) drug substitution and a detectable viral load (≥ 400 copies/ml) at 6 and 12 months 
after ART initiation. 
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iii. To determine the diagnostic accuracy (sensitivity, specificity, PPV, NPV) of self-
reported adherence (e.g. VAS, SMAQ or multi-method) and the composite marker 
including CD4 response, MCV response, missed appointment and new condition or 
symptom compared to viral load as the gold standard. 
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CHAPTER TWO - MATERIALS AND METHODS 
 
2.1 Introduction 
 
This chapter describes the methods used to collect, manage the data and perform the statistical 
analysis. It also details techniques used in dealing with the missing data in order to ensure the 
validity of the study results. First, the chapter describes the study design, the setting, how the 
sample size was arrived at and explains the study population.  
 
2.2 Study design 
 
 
This is a secondary data analysis of data collected from a prospective cohort of HIV-positive 
patients. Data were collected from ART naïve patients initiating first-line ART at Themba 
Lethu Clinic in Johannesburg from February 2012 to April 2014. At baseline, demographic and 
previous clinical informations were recorded for each HIV-positive patient prior to ART 
initiation. Clinical information, adherence to antiretroviral drugs, viral load, CD4 count and 
other routine biomarkers were assessed at 6 and at 12 months after ART initiation. Although, 
the information was collected prospectively, the object of diagnostic study is cross- sectional 
(Figure 1) (Collins et al, 2015). Therefore, the effect of the exposure in the outcome must be 
assessed at a single point during the follow-up (Steyerberg et al, 2013; Collins et al, 2015). For 
the purpose of our study, we analyzed the data using the time period (T) of 6 months as T=0  
(Collins et al, 2015).  
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                           Figure 1 TRIPOD schematic representation of diagnostic study: (Collins et al, 2015). 
 
2.3 Study Setting  
 
The data were prospectively collected at the Themba Lethu HIV Clinic, an ambulatory centre 
dedicated to the treatment of people living with HIV/AIDS, located in the city of Johannesburg 
in the Gauteng Province, north central South Africa. The Themba Lethu HIV Clinic cohort 
database is the result of collaboration between the Non-Governmental Organization (NGO), 
Right to Care, Boston University, the Clinical HIV Research Unit and the Health Economics 
and Epidemiology Research Office (HE2RO) of the University of the Witwatersrand.  
The clinic is located inside the Helen Joseph Hospital in Johannesburg, Gauteng Province. 
Themba Lethu HIV Clinic started in 2004 with the roll out of South Africa’s National ART 
treatment programme and, since then, more than 30000 HIV-positive persons have been 
enrolled for HIV treatment and care and 21000 of them have been initiated on antiretroviral 
treatment (Fox et al, 2012) with an average of 176 medical visits per day (Macleod et al, 2012). 
Patients are mostly from the Johannesburg area, the majority of them are South Africans and 
some of the patients are from bordering countries (Fox et al,2012).  
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Themba Lethu HIV clinic is a governmental clinic and operates under the South African 
National Treatment Guidelines (DOH. 2013). According to the 2013 South African ART 
treatment guideline (DOH. 2013), adult patients are initiated onto ART when their CD4 count 
is ≤ 350 cells/mm³ irrespective of WHO clinical stage. Individuals with tuberculosis, pregnant 
women or breast-feeding women are also eligible to initiate ART treatment.  Also, patients 
with WHO stage III or IV conditions are also eligible for ART treatment, regardless of CD4 
count level. Most of the HIV-positive patients (70%) are initiated onto the first-line 
combination Tenofovir-Lamivudine-Efavirenz. Patients on ART treatment are seen typically 
during medical visits at month 1, 3, and 6 and 12 months  whereas the laboratory monitoring 
is done every 6 months to one (1) year  (Fox et al, 2012). For the LCM study, laboratory 
markers were done at 0, 6, 12 and 24 months on ART. 
According to the 2013 South African ART guidelines (DOH, 2013), the first viral load should 
be measured at six (6) months and yearly thereafter following initiation of therapy. By Six 
months, patients with high adherence level should have reached viral load suppression defined 
as viral load value ≥ 400 copies/ml (2.6 Log10) (DOH, 2013). Additionally, following the 2013 
South African ART guidelines, patients have CD4+ cells levels measured every 6 months 
(DOH. 2012; DOH. 2013). Beside viral load and CD4 count, several other laboratory markers 
are routinely checked prior to ART initiation and later during clinical visits. TherapyEdge-
HIV™ (Advanced Biological Laboratories, SA, Luxembourg) is an Electronic Medical Record 
(EMR) which has been used at Themba Lethu clinic since 2009 for the management of routine 
care data (Fox et al, 2012). The application provides a platform to enter and store updated data 
on demographics, visits, laboratory results such as viral load, CD4 count, medical conditions 
and antiretroviral treatment (Fox et al, 2012). It also provides a possibility for the staff to enter 
data or consult patient’s clinical history during medical visits in order to ensure a regular update 
of patient’s information (Fox et al, 2012). TherapyEdge-HIV™ is connected to laboratory 
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results from the NHLS laboratory and also the pharmacy system (Fox et al, 2012). The quality 
of the TherapyEdge-HIV™ database is optimized with a team dedicated to verifying, checking, 
correcting errors and regularly cleaning the database (Fox et al, 2012).  
 
2.4 Study population 
The study population consisted of  HIV-positive men and women ART naïve patients older 
than 18 years of age and who initiated standard first-line ART based on the 2010 South African 
National Department of Health ART treatment guidelines (DOH, 2013). These HIV-positive 
adult patients were recruited and followed up at Thembu Lethu Clinic between February 2012 
and April 2014. Data were prospectively collected during the routine visits.  
2.4.1 Inclusion criteria 
The inclusion criteria were as follows: 
- Adult (over 18 years of age) at ART initiation and willing to consent 
- HIV-positive patient eligible to initiate first-line according to the 2013 South African 
National adult ART treatment guidelines  (DOH, 2013). 
- ART naive  
2.4.2 Exclusion criteria 
The exclusion criteria included any of the following: 
- Participants who were pregnant at enrolment or who became pregnant during the study 
- Patients transferred in from other facilities  
- Participants who had already started ART at the beginning of the study.  
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2.5 Study sample  
 
From 2012 to 2014, consecutive HIV-Positive patients on First-line ART treatment at Themba 
Lethu Clinic who fulfilled the eligibility criteria were prospectively included in the study 
database of Low Cost Monitoring of HIV in resource-limited settings (LCM). A sample size 
of 357 patients was obtained at the end of the enrolment period in 2014. For this secondary 
data analysis, the information available on LCM database was linked to the TherapyEdge-
HIV™ electronic database to generate a single dataset with 357 observations.  
We estimated that the prevalence of failing to suppress viral load will be 32%  at treatment 
initiation (Fox et al,2013) and this proportion will be around 39% at 6 months after ART 
initiation (Evans et al, 2014) .With this sample size of N=357 and a two-sided test with α=5%, 
given a difference of at least 3% in the adherence measure between males et females, and a 
within group standard deviation of VAS to be 9.03, our study will have more than 80% power 
(83.16%) for detecting an independent association of failure to suppress viral load  (HIV/RNA  
≥ 400 copies/mL) with poor adherence represented by VAS < 95% adjusted for gender, age, 
MCV response, missed appointment, new condition symptoms and drug substitution 
(Vittinghoo et al, 2012; STATA, 2011). 
 
2.6 Data sources and measurement 
2.6.1 Data sources  
The data used in this study was obtained from 2 data sources, namely the study database of the 
Low-Cost Monitoring of HIV in resource-limited settings (LCM) and the TherapyEdge-HIV™ 
database. Individual records from LCM database were linked to routine care data drawn from 
TherapyEdge-HIV™. The linkage was done using a unique identifier number (TE number) and 
after removal of personal information. 
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The LCM study was a prospective cohort study in which patients on first-line ART treatment, 
upon meeting the eligibility criteria, were successively enrolled since its start in 2010. After 
enrolment into the cohort, patients come at the clinic every 6 months. At each patient’s visit, 
demographic and clinical information were gathered by the study staff and stored in an Excel 
spreadsheet (Table 1).  
Table 1  Data Source of different informations collected during the study.  
 
MCV: Mean cell volume. ART: Antiretroviral treatment. NDoH: National Department of Health. WHO: World Health Organization. LCM: Low cost 
monitoring. DOH: Department of Health 
                             Database source 
Variables TherapyEdge-HIV™ LCM 
Eligibility criteria 
 
 
According to DOH 
guidelines 
 
≥ 18 + not pregnant and not transferred in 
 
Demographic 
characteristics  Same Same 
ART regimen  Same Same 
 
 
Medical visit 
 
1, 3, 6 months and every 6 
months thereafter 
 
                            0, 6, 12, 24 months 
 
 
Laboratory tests                                               
(serum lactate, albumin) 
Standard of care according 
to NDoH guidelines 
 
 
                             0, 6, 12, 24 months 
 
 
 
Extra laboratory 
monitoring: Adherence,  
serum lactate, albumin, 
total lymphocyte count As clinically indicated        0, 6, 12, 24 months 
Viral load                                                6, 12 months 0 months 
 
WHO stage at ART 
initiation  
 
0 month 
 
             0, 6, 12, 24 months 
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2.6.2 Definition and measurement of outcomes and exposures 
 
2.6.2.1 Adherence measures       
 
At Themba Lethu Clinic, adherence to treatment was assessed based as part of the Low-Cost 
Monitoring of HIV in resource-limited settings (LCM) project at 6 and 12 months of follow-
up. Data were collected by the health care workers who administered the tools at during each 
follow up visit. The assessment method used four (4) self-reported adherence (SRA) measures 
namely: self-reporting, Visual Analogue Scale (VAS), pill identification test (PIT) and the 
Simplified Medication Adherence Questionnaire (SMAQ) (Appendix D). Each of these 
methods has been validated in previous studies (Knobel et al, 2002). The result of each method 
of adherence measurement was classified as either positive or negative given a conventional 
threshold. 
Previous studies have shown that the validity of applying a combination of tests is higher when 
compared to a single test to assess adherence to antiretroviral treatment. Therefore, WHO 
recommends a multi-method approach when measuring a patient’s adherence to ART (Steel & 
Joshi, 2007). Thus, in our study three (3) self-reported adherence (SRA) measures were 
combined into a single adherence assessment tool. The method to derive a single adherence 
assessment tool from the three (3) SRA individual methods is described below. 
❖ Self-report (SR) 
In the self-report, adherence is based on the patient’s assessment of the number of pills taken 
in the last week compared to the actual dose that should have been taken. This method also 
includes questions that attempt to assess whether the patient did stop or sometimes had 
difficulties taking the medication correctly as prescribed during the last visit. Thus, the self-
report tool also addresses the underlying causes of low adherence. To collect the data on 
adherence, the health worker used a questionnaire. There are four questions on which the 
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patient responds with either “yes” or “no”. A patient who answers “no” to all the four questions 
is recorded as highly adherent, but the one whose answer is “yes” to one of the items is recorded 
as moderately adherent. When a patient responds “yes” to two (2) or more questions, he or she 
is rated as poorly adherent.   
❖ Visual analogue scale (VAS) 
The Visual Analogue Scale is used to assess adherence to the antiretroviral treatment for four 
weeks. With the visual analogue scale, the patient is asked to mark on a scale of measurement 
from 0 to 100%, the number or proportion of doses taken to assess his or her adherence to the 
medication over the past 3 or 4 weeks. Upon the request of the health worker, the patient ranks 
his or her adherence level on a graduate scale usually a ruler marker from 0 to 100%. The point 
on which the patient places his or her finger reflects how much of the drug he or she has taken 
over the previous 3 or 4 weeks and is recorded by the health worker as the patient’s own 
adherence score. Three levels of score results are defined: 95% or more, 75-94% and less than 
75%. A patient who score 95% or more at the VAS is considered as highly adherent while a 
patient who score between 75-94% at the VAS then the overall adherence is moderate. Finally, 
when a patient scores less than 75% at the VAS then the overall level of adherence is “low” 
(Steel & Joshi, 2007). 
❖ Pill identification test (PIT) 
In this method, the health worker asks the patient during a face-to-face interview to visually 
identify the different categories of drugs that were dispensed to him or her. For each drug, the 
patient must give the following information: name of medication, number of pills per dose and 
the time the patient usually takes the medication. This identification test is performed for each 
single drug included in the patient’s antiretroviral drug regimen.  After the patient has provided 
the responses, these are collected on a sheet of paper and then classified as true or false by the 
   
21 
 
health worker. A patient who knows the dose, time and the instructions to the ART regimen is 
classified as a highly adherent patient, a patient who knows the Dose and Time to take the 
medicine is classified as moderately adherent, and a patient who only knows the dose or was 
confused is classified as poorly adherent.  
❖ Simplified Medication Adherence Questionnaire (SMAQ) 
The SMAQ is a tool that enables the researcher to assess how adherent the patient was to 
medication during the last weeks or last month using quantitative and qualitative questions 
(Knobel et al, 2002). In the LCM study, the SMAQ was used to collect information on 
adherence over the previous 3 months. The SMAQ score ranged from 0 to 7 with 0 
corresponding to 100% adherence (Appendix D). For this present study, a patient was 
considered as positive or non-adherent with the SMAQ adherence tool when a positive 
response was given to one of the questions, or the patient did not take any medicine over the 
past weekend, or had missed taking the medicine for more than two days over the past 3 months  
(Knobel et al, 2002). 
❖ Multi-method approach 
In our study, the multi-method approach tool included self-reports combined with VAS and the 
pill identification test (PIT). Overall adherence assessment with the multi-method approach 
was rated into 3 categories: high, moderate and low.  A high level of adherence corresponds to 
patients who reported “No” to all questions with self-reporting, had a VAS score ≥ 95% and 
who knows the dose, time and instructions on how to take the drugs. A moderate adherence 
level was given to patients who responded “Yes” to one question with the self-report, had a 
VAS value between 75% and 95% and who additionally knows the dose and appropriate time 
at which he should take the drug. A patient who did not meet the above-mentioned criteria was 
classified as poorly adherent with the multi- method approach. 
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2.6.2.2 Baseline and follow-up variables  
 
The baseline demographic and clinical variables were assessed 90 days prior to ART initiation 
and 7 days after. The clinical follow-up variables were also collected during the medical visits 
after ART initiation at 6 and 12 months. All the laboratory tests were performed at the same 
time during the medical visits. The baseline and follow-up variables were categorized into three 
groups which are described below: 
- Socio-demographics 
• Age in years at the time of ART initiation 
• Sex categorized into male or female 
• Level of education: illiterate or not yet schooled, primary, secondary, tertiary and 
beyond 
• Current employment status of patients. 
• Nationality: South African or foreign national 
 
- Biological 
In addition to the demographics and adherence measurements, 24 variables (clinical and 
laboratory markers) were selected as potential predictors of adherence to ART treatment and 
included in the univariate analysis. These variables were selected following a literature review 
and from previous studies that assessed factors associated with adherence to ARV treatment. 
Furthermore, some immunological and clinical markers have been previously identified as 
predictors of adherence to ARV treatment in diagnostic prediction models using retrospective 
datasets. The values of each clinical marker at 6 and 12 months were dichotomized using cut-
off points suggested from previous studies and for easy use of the diagnostic prediction model 
in routine clinical practice (Lynen et al, 2009; Segeral et al, 2010; Chauhan et al,2011). The 
following clinical and biomarker variables were extracted for each patient during the medical 
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visit, first prior to the ART initiation therapy and then consecutively at 6 and 12 months on 
ART. 
 
- Baseline biological variables 
• WHO stage: either stage I/II or stage III/IV based on WHO classification of disease 
severity 
• ART drugs regimen: Tenofovir (TDF)-based regimen or stavudine (d4T)-based 
regimen or other first-line ARV regimens. 
• Tuberculosis: Tuberculosis at ART initiation. 
• CD4 (cells/mm3) 
• Body Mass Index (kg/m2) 
• Haemoglobin (g/dL) 
• Mean cell volume (MCV) (fL) 
• Platelet count (10^2/mm3)    
• Total lymphocyte count (10^3/mm3)  
• Serum lactate (mmol/L) 
• Albumin (g/l) 
• Mean corpuscular haemoglobin (pg) 
• Haematocrit (volume %) 
• Red blood cells (million cells/μl) 
• Systolic and diastolic blood pressure (mmHg) 
 
- Biological variable changes over the previous 6 months (Table 1) 
• Failing to increase CD4 count by ≥ 50 cells/mm3 
• BMI < 18.5 kg/m2 
• BMI drop over the previous 6 months of > 2.5%  
• Haemoglobin drop over the previous 6 months of > 1g/dl 
• Change over the previous 6 months in MCV < 14.5 fL 
• Serum lactate below 2 mmol/L 
• Serum albumin decreased or unchanged over the previous 6 months 
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• Platelet count < 150/mm3 after 6 months 
• Total lymphocyte count < 2,000 cells/mm3 
• Mean corpuscular haemoglobin < 2.7 pg  
• Number of missed ARVs visits ≥ 7 days 
 
Table 2 Summary of different cut-off values used by type of laboratory markers. 
Biomarkers Cut-off value References 
CD4 count  
Failing to increase by ≥ 50 
cells/mm3 at 6 months; Failure to 
increase by ≥ 100 cells/mm3 at 
12 months. 
Van Griensven et al, 2014;  Evans et al, 
2014; Robbins et al, 2010 
Body Mass Index 
(BMI) 
 
BMI drop over the previous 6 
months of > 2.5% Messou et al, 2008   
Body Mass Index 
(BMI) BMI < 18.5 kg/m2   Evans et al, 2014 
Criteria for anaemia 
 
 
Women: Haemoglobin < 7.4 
mmol/L  WHO, 2001 
 Men: Haemoglobin < 8 mmol/L WHO, 2001 
Haemoglobin (Hb) 
Haemoglobin drop over the 
previous 6 months   > 1g/dl Van Griensven et al, 2014 
Mean corpuscular 
volume (MCV) 
Change over the previous 6 
months in MCV < 14.5 fL 
Romanelli et al, 2002; Steele et al, 2002 ; 
Lynen et al, 1999; Colebunders et al, 
2006 
Serum Lactate  
Serum lactate below 2 mmol/L 
after 6 months  Desai et al, 2003 
Albumin  
Albumin decreased or 
unchanged over the previous 6 
months  Chauhan et al, 2011  
Platelet count  
Platelet count < 150/mm3 after 6 
months  
 De Santis et al, 2011; Zetterberg et 
al,2013 
Total lymphocyte 
count  
Total lymphocyte count < 2,000 
cells/mm3  
Lau et al, 2003; Schreibman and 
Friedland 2004  
Mean corpuscular 
haemoglobin 
(MCH)  
Mean corpuscular haemoglobin 
< 2.7 pg after 6 months  Evans et al, 2014 
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2.6.2.3 Study outcomes 
 
The outcome of interest was poor adherence to ART assessed through the failure to supress 
viral load at periods since ART initiation. This outcome was defined by a single elevated 
plasma viral load equal to or above 400 copies/ml (HIV-1 RNA copies ≥400 copies/ml) at 6 or 
12 months post ART initiation. Viral load is considered as the standard reference method to 
classify HIV-positive patients on ART as being adherent or non-adherent (Evans et al, 2014). 
The viral load was assessed at 6 and 12 months, however, during the primary data collection, 
data on viral load measurement were not available for all patients at these times. The plasma 
viral load was not available in the LCM database, therefore we used the electronic patient 
medical record for viral load measures. Viral load between 4-9 months and between 10-14 
months were respectively considered as plasma viral load at 6 and 12 months respectively (see 
data management section). Furthermore, the viral load was also considered as the gold standard 
to assess the diagnostic accuracy of three measures of adherence based on questionnaires 
(VAS, SMAQ, Multiple approach method) at 6 and 12 months after ART initiation. 
2.6.3 Data management  
Data for each patient were entered into the LCM database and stored in an Excel spreadsheet. 
These data included: age, gender, ARV regimen at ART initiation, adherence to ARV treatment 
at 6 months and 12 months, body mass index, laboratory results (mean cell volume, 
haemoglobin, serum lactate, platelet count, mean corpuscular haemoglobin, and the viral load) 
at 6 and at 12 months. For the secondary analysis, the database was transferred to STATA and 
transformed from a long to a wide format STATA dataset.  We used clinical file number (TE 
number) to link the LCM study datasets to the Themba Lethu Clinic electronic medical record 
system, TherapyEdge-HIV™ (TE) where the patient’s records are kept and to the National 
Health Laboratory Services (NHLS) laboratory data (e.g. CD4 counts and viral load at 6 and 
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12 months from TE) to find, missing, incomplete or erroneous data. Some clinical information 
such as missing ARV visits and WHO clinical stages (CDC, 2005) were stored in a SAS format 
Therefore, we also used the SAS system for Windows, version 9.2  (SAS Institute, Cary, North 
Carolina, USA). We used the software Stat/Transfer version 13 to convert files from a SAS 
data file to a STATA data file (Stata Statistical Software: Release 13. College Station, TX: 
STATACorp LP). Then, we used the unique clinical ID number to merge these pieces of 
information with the patients in the LCM study database. This procedure allowed us to form a 
single dataset including the baseline characteristics and the follow-up variables at 6 and 12 
months in a wide format. All the duplicate observations were dropped and individuals who did 
not meet the inclusion criteria were identified and numbered at baseline, 6 and 12 months of 
follow up. 
For the analysis, some continuous variables were re-coded into binary or categorical variables. 
Age was categorized as binary variable code 0/1 using the threshold of 35 years old (>35=1; ≤ 
35=0). Haemoglobin levels vary with age, gender at different stages of pregnancy, with 
altitude, smoking and, in certain cases genetic factors (Hurtado & Merino, 1945; WHO, 2001). 
We considered haemoglobin levels below which anaemia is present as 7.4 mmol/L and 8.2 
mmol/L haemoglobin for non-pregnant women and adult men respectively (WHO, 2001). 
To assess adherence to the ART treatment, the variable viral load was re-coded into a binary 
variable (1-Yes/0-No), patients with a viral load either equal to or above 400 copies/ml were 
considered as non-adherent (≥ 400 copies/ml and < 400 copies/ml). The CD4 count was re-
coded to a four-level categorical variable with the following categories: 0: < 50; 1: 51-100; 
2:101-200; 3: 201-350, 4: > 350 cells/mm3. The ART regimen was recoded to three 
combination regimens that were more meaningful clinically; individuals were classified into 
one of the following categories: Tenofovir (TDF)-based regimen, stavudine (d4T)-based 
regimen and “other” for the regimen that contained neither TDF nor d4T. The TDF-based 
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regimen was an antiretroviral medicine containing Tenofovir (TDF) with a nucleoside reverse 
transcriptase inhibitor (NRTI) and a non-nucleoside reverse transcriptase inhibitor (NNRTI), 
either efavirenz (EFV) or Nevirapine (NVP). The d4T-based regimen included stavudine (d4T) 
with another NRTI and NNRTI, either EFV or NVP. Body mass index (BMI) was re-coded 
into two categories: (Yes/No) using a threshold value of 18.5 kg/m2 (Yes < 18.5; No ≥ 18.5). 
Nationality was categorized into two groups: either south-African or national foreign. To make 
the use of the diagnostic model easier, all the immunological and laboratory markers over the 
previous 6 months were transformed from continued to binary variables (Yes/No). We used 
the cut-off values known from previous studies diagnostic prediction models found in the 
literature (Chauhan et al, 2011; Evans et al, 2012; Lau et al, 2003; Lynen et al,2009; 
Schreibman & Friedland, 2004; Messou et al, 2008). For some laboratory marker variables, we 
determined the percentage of change (PC) after 6 months as the amount of change during the 
past 6 months relative to the initial value of that variable at the start of the period.  
PC =
(6 month value−baseline value) 
baseline value
∗ 100) 
 
2.7 Statistical methods 
2.7.1 Exploratory Analysis 
We describe the distribution of continuous variables using numerical and graphical methods 
such as histogram, normal quantile-quantile (or Q-Q) plot. For each continuous variable, the 
graphics were depicted (histograms and normal Q-Q plot) to compare the sharpness of the 
distribution to a normal distribution using the functionalities of STATA graphics. Secondly, 
when there was evidence of skewness of the distribution with the graphical representations, 
testing for departures from normality was done. The Shapiro-Wilk test for normality was used 
to assess the evidence of deviation from normal distribution. A p value < 0.05 means the 
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hypothesis that the variable is normally distributed can be rejected. For variables that were 
skewed, we used a log-transformation (𝑙𝑜𝑔10) to conduct the analysis and later the results were 
expressed on the original scale. 
 
2.7.2 Descriptive Analysis 
During the primary data collection, some of the predictors and outcomes were not measured in 
all patients. Therefore, prior to the descriptive and inferential analysis, we reported the 
proportion of missing data for the outcome, demographic and clinical predictors at 6 and at 12 
months. We used an approach of complete case analysis to handle the missing data. We 
reported the number of patients available at baseline, at 6 and at 12 months, and if an outcome 
was missing, the patient was excluded from the analysis. The number included at baseline of 
participation at baseline, 6 and 12 months was based on the inclusion and exclusion criteria at 
each stage (Figure 2). Continuous variables were summarized by the mean and the standard 
deviation, or median with interquartile range. Variables that were normally distributed were 
summarized with the mean and standard deviation and variables while the non-normal 
distribution or skewed were summarized with the median and interquartile ranges (IQR). 
Categorical variables were summarized by giving their frequencies.  
 
2.7.3 Inferential Analysis 
To compare continuous variables, we used an unpaired t-test if the variable was normally 
distributed. When continuous variables were compared from baseline to the previous 6 months, 
a paired t-test was done. In the case of skewed distribution, we used a non-parametric variant 
of the t-test such as the Mann-Whitney U-test. To compare categorical variables, we used cross-
tables with corresponding chi-square or Fisher exact test. 
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For self-reported adherence such as the visual analogue scale, the self-report, the SMAQ, and 
the multiple-approach method at 6 and 12 months, we defined and calculated the sensitivities, 
specificities, positive predictive values (PPV) and negative predictive values (NPV) comparing 
their performance with the gold standard defined by a viral load that is detectable (≥ 400 
copies/ml). Sensitivity (Se) was defined as the number of true positives over the number of 
actual positives with viral load. Specificity (Sp) was defined as the number of true negatives 
(negative with the self-reported adherence methods) over the number of negative with the viral 
load. Positive predictive value (PPV) was defined as the proportion of patients with a detectable 
viral load (VL ≥ 400 copies/ml) in those with a positive test result with the self-reported 
adherence assessment tools. Negative predictive value (NPV) was defined as the absence of a 
detectable viral load (VL ≥ 400 copies/ml) in those with negative test results using self-reported 
adherence assessment tools. All statistical tests were two sided and a p value of less than 0.05 
was regarded as statistically significant. 
2.7.3.1 Modified Poisson regression model 
 
For a follow up study or in a study with common outcomes, the relative risk represents the 
estimated measure of risk instead of the odds ratio (McNutt, 2003). We planned to use a log 
binomial regression model to estimate an adjusted relative risk at 6 and 12 months. However, 
this method failed to converge in STATA. Instead, we used a modified Poisson  generalized 
linear model (GLM)  with a robust or “sandwich” variance-estimate that adjusts  for clustering 
between individuals in the dataset model at 6 and 12 months of follow up (Hardin et al, 2012; 
Yelland et al, 2011). The incidence rate ratio obtained from the modified Poisson generalized 
linear model  can be used to estimate the relative risk in a cohort study (McNutt,2003 ;Newton 
et al, 2010). This method is an extension of the Poisson generalized linear model available in 
STATA (Newton et al, 2010). We applied  a method of variable selection called purposeful 
selection of variables (Hosmer et al, 2013). With this method, the selection starts with the 
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univariate analysis of each independent variable. We used a cut-off value of 0.25 instead of 
0.05. Any variable with a value equal to or less than 0.25 in the univariate Poisson regression 
model was retained for the multivariate model. Thus, the multivariate model included all the 
significant variables at univariate analysis. The importance of each predictor was assessed 
using the statistical significance of the regression coefficients or the log likelihood ratio test. 
Any variable that did not have a significant regression coefficient was removed and a smaller 
model was set up. 
To assess for confounding during the process of multivariable selection, we compared the 
estimated coefficient in the smaller model with the previous values in the larger model for each 
variable. Variables, when excluded, changed the coefficient of remaining variables of Δβ > 
20% were considered as potential confounders and added back in the model. The variables that 
were not significant at the univariate analysis were added back to the model and their 
significance assessed in the presence of other significant variables. Variables that remained 
significant in the model and that did not add significant contributions were finally removed. 
With the main effect model, we assessed for interaction among the variables in the model 
including any possible interaction term to the main effect model. We assessed the statistical 
significance of each interaction term using a likelihood ratio test and interaction terms that were 
significant were added back to the model (p value < 0.05). Finally, we added demographic 
characteristics such as age, sex and predictors well known from previous research but not 
significant in our model. Subsequently, the goodness of fit of our final model was compared 
using the values of the Akaike Information Criterion (AIC). The model with a smaller AIC and 
smaller deviance was considered as a better fitting model. Finally, to test whether our Poisson 
generalised linear model was correctly specified, we used the link test in STATA post-
estimation command. The link test is based on the idea that if a regression is properly specified, 
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one should be able to find no additional independent variables that are significant except by 
chance (STATA, 2011). 
2.7.4 Elaboration of the diagnostic prediction model at 6 and 12 months 
 
We used the result of the multivariate regression model to develop a new diagnostic prediction 
model. The appropriate design for a diagnostic prediction model is a cross sectional study 
(Collins et al, 2015), so we developed two models to estimate the probability that the non-
adherence to ART therapy is present or absent at 6 and 12 months.  We applied a scoring system 
based on the Spiegelhalter and Knill-Jones approach currently used in many diagnostic 
prediction studies. With this method, each adjusted regression coefficient in the final model is 
rounded to the nearest integer and the result is multiplied by a factor of 10 (Seymour et al, 1990 
; Evans et al, 2013). Summing the risk score gives for each patient its total predicted probability 
of adherence to ART at 6 and 12 months. We observed the diagnostic accuracy of each scoring 
system and of the self-reported adherence methods at 6 and12 months by computing the area 
under the curves (AUC) value of the Receiver Operating Characteristics (ROC) curve (Hanley 
& McNeil, 1982). Based on the ROC curves, we defined the appropriate cut-off value 
corresponding to the point with the highest validity. Subsequently, we calculated sensitivity 
(Se), specificity (Sp), positive predictive values (PPV) and negative predictive values (NPV) 
of these cut-offs points compared to gold standard of detectable plasma viral load. 
 
2.7.5 Sensitivity Analysis  
As with routine clinical data, there was missing data in the LCM database. This may result in 
the estimation and affect the accuracy of the diagnostic model at 6 and 12 months (Donders et 
al, 2006). Therefore, we implemented a multiple imputation technique to fill in the missing 
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values in the predictors and the outcome. We assumed that data are missing at random (MAR) 
with a pattern that is closed to monotone. In a MAR situation, the probability of a missing value 
on a predictor is independent of the value of that predictor but depends on the observed values 
of other variables (Collins et al,2015).Therefore, each of the conditional distribution of the 
missing values can be estimated from the observed data or other variables. Following our 
assumption of MAR, we used the approach of the Multiple Imputation by Chained Equations 
(MICE) (Royston & White, 2011) and applied this technique with the ICE program in R 
Software (R Foundation for Statistical Computing, 2014). 
 
In multiple imputation, the inclusion of many predictors increases the plausibility and reduces 
the bias in the imputation model (Donders et al, 006; Steyerberg & Van Veen, 2007; Royston 
& White, 2011), furthermore, the imputation model should be as large as the model intended 
to use for statistical modelling (Van der Heijden et al, 2006). Therefore, for a reliable 
estimation, we included all the variables that were in the univariate analysis and the outcome 
variables were always included as predictors in the imputation process. To deal with non-
normality distribution, continuous variables with missing values and with non-normal 
distribution were transformed to approximate normality by means of logarithmic 
transformation in the imputation model. Then, to get the imputed values, each variable was 
back-transformed to its original scale before fitting the multivariate model for analysis and 
comparison. To reduce the sampling variability, a total of 10 completed datasets were created 
with the use of the seed option to ensure that the imputed values are reproducible. We used 
Rubin’s rule to produce an overall estimation of each regression coefficient and model 
performance measures with the imputed dataset. Finally, we conducted a sensitivity analysis 
to compare the robustness of the estimations between the case complete analyses where 
subjects with missing values are excluded from the analysis with the cases where missing data 
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were filled. Specifically, we assessed whether the complete case analysis (CCA) with the 
multiple regressions from the imputed dataset were different and whether the multiple 
imputations improved the performance of the diagnostic prediction model or its validity at 6 
and 12 months 
 
2.8 Ethics clearance 
 
The primary study was approved by the Human Research Ethics Committee of the University 
of the Witwatersrand and informed consent for participation in the primary study was obtained 
from all participants. The original ethical approval was obtained in June 2010 (Clearance 
Certificate M10418) and re-approved in 2014. For the secondary data analysis, a protocol was 
submitted to the Wits Human Research Ethics Committee. This study protocol was approved: 
clearance Certificate M140918 (Appendix B). There was no personal identification in the 
dataset that was provided, and the patients are only identified using the unique ID number 
included in the LCM database and linked to the TherapyEdge-HIV™. For this secondary data 
analysis, an approval letter from the principal investigator, granting access to the data, was 
obtained (Appendix C). 
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CHAPTER THREE - RESULTS 
 
 
OBJECTIVE 1 
To compare the demographic and clinical characteristics of patients on first line antiretroviral 
treatment with a detectable viral load (VL ≥ 400 copies/ml) with those with a viral load < 400 
copies/ml at 6 and 12 months after ART initiation 
3.1 Organization of the study cohort and total number of participants 
 
 
Between 2010 and 2014, of a total of 357 HIV-positive patients that initiated ART for the LCM 
cohort study, 4 (1.1%) were not eligible and a total of 353 met the inclusion criteria. Of the 4 
patients who were not eligible, there were 2 pregnant women and two others were not on first-
line regimen. This left 353 eligible patients at baseline from Themba Lethu Clinic (see 
flowchart (Figure 2). Out of the 353 eligible patients who initiated antiretroviral treatment, 57 
(16.1%) individuals were excluded from the analysis at 6 months:  25 were lost to follow up 
after ART initiation; 17 were transferred out, 12 died and 3 were pregnant before the 6-month 
visit. Therefore, among 353 patients at baseline data collection, 296 were eligible for the 
analysis at 6 months and of them 239 (80.7%) had their plasma viral load assessed. Out of 296 
patients who reached the 6-month follow-up, 6 (2.0%) patients were excluded: one patient was 
lost to follow-up and 5 were pregnant women before 12 months. This left 290 participants 
eligible for the analysis at 12 months, of these, 119 (41.0 %) had a plasma viral load assessed 
at the end of the study period 
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Figure 2 Flowchart of the participants in LCM study. 
 
The flowchart indicates how the final eligible study cohort was obtained from the participants recruited within the LCM study, the total 
number of patients at 6 and 12 months and the proportion with a viral load (outcome) assessed during the follow-up at 6 and at 12 months. 
 
 
3.2 Baseline demographic characteristics  
 
Of the 353 patients in the baseline study population, more than half were males with the ratio 
of male to female being 178 males to 100 female patients and a mean age at ART initiation of 
37.6 years (standard deviation = 8). Education level ranged from beyond secondary school 
(15.0%) to individuals with no education (3.7%). Of the 353 patients at baseline, 85.3% were 
Eligible participants (n = 353) 
Excluded (n = 4) 
 
- Pregnant: n = 2 
- Not on first line regimen = 2 
 
 
Total recruited at baseline data collection 
(n = 353) 
 
Number of participants at 6 month of 
data collection (n = 296) 
     -Viral load assessed: n = 239 (80.7%) 
 
- Lost to follow up n = 25 
- Self-transferred: n = 17 
- Deceased: n = 12 
- Pregnant: n = 3 
 
Number of participants at 12 months of 
data collection (n = 290)  
      -Viral load assessed: n = 119 (41%) 
Excluded (n = 6) 
-  Lost to follow up: n = 1 
-  Pregnant: n = 5 
 
 
Participants screened for the LCM study 
(n = 357) 
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South African while the rest where from neighboring countries. Among the patients, only small 
proportions (4.5%) smoked in the past or were still smoking and 7.0% reported alcohol use. 
There were minimal missing values at baseline. The maximum percentage was with the 
variable education with a proportion of 3.1% out of 353 observations (Table 3).  
 
3.3 Baseline clinical characteristics at ART initiation 
 
Of the 353 patients included at baseline, 299 were either WHO stage I or WHO stage II and 
the majority (87.5%) of patients were initiated on a Tenofovir-based regimen. The median 
baseline CD4+ count was 196 cells/mm3 (IQR: 98 - 268.5). Thirty (8.5%) individuals had a 
CD4+ count above 350 cells/mm3 and 179 (50.7%) were below 200 cells/mm3, meaning that 
half of the patients were under the threshold value below which treatment should not be delayed 
(DOH, 2013). At baseline, the median albumin level was 40 g/dl (IQR: 28 - 51). Body Mass 
Index (BMI) values ranged from 13.6 kg/m2 to 59.4 kg/m2 and 22 (6.5%) patients were 
underweighted with a BMI below 18.5 kg/m2. At enrollment, fewer than five percent had 
anaemia defined as haemoglobin level < 7.4 mmol/L or < 8 mmol/L respectively for non-
pregnant women and adult men. Slightly more than 10% of patients had tuberculosis prior to 
ART initiation (Table 4).  
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Table 3 Baseline demographic characteristics of 353 ART- naive patients. 
 
†All data in percentages, or as indicated:  mean ± Standard deviation or median with interquartile range (IQR) 
*Still smoking or previously smoking *Still alcohol user or previously alcohol user. 
 
 
 
 
 
Characteristics Number (N= 353) Percentage % 
Age at initiation (mean ± standard 
deviation) 
353 37.6 (± 8) 
Data missing 00 00% 
Age category at initiation   
35 years old 146 41.4% 
< 35 years old 207 58.6% 
Data missing 00 00.0% 
Sex   
Male 226 64.0% 
Female 127 36.0% 
Data missing 00 00.0% 
Employment status at initiation   
Yes 206 58.4% 
No 147 41.6% 
Data missing 00 00.0% 
Level of education   
Beyond secondary school 15 15.0% 
Secondary school 257 72.8% 
Primary school 25 7.1% 
Illiterate/Not yet schooled 13 3.7% 
Unknown 32 9.0% 
Data missing 11 3.2% 
Nationality   
South African 301 85.3% 
Non South African 51 14.5% 
Data missing 1 0.2% 
Smoking*   
Yes 25 7.1% 
No 322 91.2% 
Data missing 6 1.7% 
Alcohol use*   
Yes 16 4.5% 
No 331 93.7% 
Data missing 6 1.7% 
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Table 4 Baseline Clinical characteristics at ART initiation. 
Baseline characteristics Total (N) 
 
Median (IQR) or proportion% 
 
CD4 cell count (cells/mm³): median 
(IQR)   
352 196 (98 - 268.5) 
Data missing 1 0.3% 
CD4 cell count (cells/mm³)                                        
<50                                                                               46  13.0% 
50- 100                                                                         44                                        12.5% 
>101-200                                                                                                                               89 25.3% 
201-350                                                                                                                      143 40.6% 
>350                 30 8.5% 
Data missing                  1 0.3% 
Body mass index (kg/m²): median 
(IQR)   
339  23.5 (16.3 - 43.8) 
Data missing % 14 4.0% 
Body mass index (kg/m²) < 18.5    
Yes 22 6.5% 
No 317 93.5% 
Hemoglobin (g/dl): median (IQR)   352 12.3 (11 - 13.5) 
Data missing 1 0.3% 
Hemoglobin (mmol/L) of < 8 or 7.4     
Yes 9 2.6% 
No 343 97. 4% 
Mean corpuscular volume (100 fL): 
median (IQR)   
352 89.1 (84.8 - 92.3)      
Data missing 1 0.3% 
Mean corpuscular volume of <100 fL    
Yes 348 98.9% 
No 4 1.1% 
Lactate (mmol/L): median (IQR)   347  2 (1.8 - 2.4) 
Data missing 6 1.7% 
Mean corpuscular hemoglobin (pg.): 
median (IQR)   
352  29.9 (18.2 - 31.1) 
Data missing 1 0.3% 
Albumin (g/dl): median (IQR)   352 40 (28 - 51) 
Data missing 1 0.3% 
Platelet count (102cells/mm³):  median 
(IQR)   
344 
  
225 (181 - 277.5) 
Data missing 9 2.5% 
Platelet count < 150 (cells/mm³)    
Yes 30 8.7% 
No 314 91.3% 
Total lymphocyte count (10^3/mm³): 
median (IQR)   
352 99.7%  
Data missing 1 0.3% 
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      †All data in percentages, or as indicated: 1 mean ± standard deviation   or median with interquartile range (IQR) 
        TDF : Tenofovir Diproxil Fumarate ; d4T : Lamuvudine. 3TC : Lamivudine ; FTC : Emtricabine ; NVP : Nevirapine ; EFV :       
        Efavirenz. Another Dirst-line regimen. ZDF-EFV-3TC and TDF-3TC-AZT. IQR: Interquartile range. WHO: World Health Organization. 
 
 
 
 
 
 
 
 
 
Total lymphocyte count ⩽ 2000 
cells/mm³ 
   
Yes 70 80.1% 
No 281 19.9% 
Red bloods cells (106 cells/μl): median 
(IQR)   
Data missing 
352 
1 
4.1(3.76 - 4 .49) 
0.3% 
White bloods cells (103 cells/μl): 
median (IQR) 
Data missing   
352 
1 
4.1(1.8 - 12.6) 
0.3% 
Hematocrit:(103 cells/μl): median 
(IQR) 
351 368 (217- 484) 
Data missing 2 0.5% 
Low hematocrit (volume%) ≤ 50%   
No 312 88.4% 
Yes 39 11.6% 
Systolic blood pressure (mmHg): 
median (IQR)   
Data missing 
 
351 
2 
76 (70 - 83) 
0.5% 
Diastolic blood pressure: (mmHg) 
median (IQR)   
Data missing 
 
351 
2 
117 (109 - 130) 
0.5% 
WHO stage at ART initiation (%)   
I or II 299 84.7% 
III or IV 48 13.6% 
Data missing 6 1.7% 
Tuberculosis at ART initiation (%)    
Yes 36 10.2% 
No 313 88.7% 
Data missing 4 1.2% 
Antiretroviral treatment at ARV (%) 
initiation  
  
TDF-3TC/FTC-NVP/EFV 309 87.5% 
d4T -3TC/FTC-NVP/EFV 39 11.1% 
Other first-line regimen  4 1.1% 
Data missing 1 0.3% 
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3.4 Comparison of demographic and clinical characteristics of 296 HIV-infected patients 
with detectable and undetectable viral loads at 6 months 
 
 
Table 5 shows a distribution of demographic and clinical characteristics by plasma viral loads 
at 6 months of ART therapy. Out of the 296 patients that reached the 6-month follow-up, 239 
(80.7%) had their plasma viral load assessed. Of those 239 patients, 72 (30.1%) did not 
experience viral load suppression. 
 
- Comparison of demographic characteristics at 6 months 
 Of the 72 patients with detectable plasma viral load, nearly 42.0% were male, 62.5% of them 
were aged above 35 years old and more than half of them attained a secondary education. 
Patients with undetectable plasma viral load at 6 months were more likely to be females 
(68.0%) or educated and 58% of them were aged above 35 years. The majority of the 72 
patients with detectable plasma viral load at 6 months (61.0%), were unemployed. The 
proportion of patients that did not suppress viral load is slightly higher among smokers 
compared to non-smokers, being 37.5% and 29.9% respectively. 
 
- Comparison of clinical characteristics at 6 months 
Table 5 shows that baseline clinical characteristics were almost similar between those who 
experienced viral load suppression and those who did not. Among the two (2) groups, most of 
patients were initiated on a TDF-based regimen. Additionally, the clinical characteristics were 
almost well balanced although HIV-positive patients with detectable viral load appeared more 
suppressed.  
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Table 5 Comparison of demographic and Clinical characteristics of 296 HIV-infected patients with 
detectable viral load at 6 months. 
  VL at 6 months 
No VL at 6 
months 
  
Variables 
VL ≥ 400  
(n = 72) 
VL < 400 
 (n = 167) 
        (n = 57) p value     
 Age                           
 > 35 years old 45 (62.5%) 98 (58.7%) 35 (39.6%) 
0.381 
 ≤ 35 years old 27 (37.5%) 69 (41.3%) 22 (61.4%) 
 Sex       
 Male 30 (41.7%) 53 (32.0%) 17 (29.8%) 
0.917 
 Female 42 (58.3%) 114 (68.0%) 40 (70.2%) 
 Education   
 
   
 Beyond secondary 
school 
7 (8.2%) 5 (2.4%) 5 (8.7%) 
  
 Secondary school 47 (67.1%) 120 (73.0%)   41 (71.9%) 0.165 
 Primary school 7 (9.6%) 13 (8.0%) 2 (3.5%)   
 Illiterate/Not yet 
schooled 
4 (6.8%) 6 (4.3%) 6 (10.5%) 
  
 Unknown 6 (8.2%) 19 (12.3%) 3 (5.2%)   
 Unemployment        
 Yes  28 (39.5%) 66 (39.5%) 24 (42.0%) 0.890 
 No 44 (61.1%) 101 (60.5%) 33 (58.0%)   
 Nationality        
 South African  64 (90.1%) 139 (83.2%) 50 (87.1%) 0.434 
 Non South African 7 (9.9%) 28 (16.7%) 7 (12.9%)   
 ART regimen at initiation      
 TDF-based regimen  61 (84.7%) 145 (86.8%) 50 (87.7%)   
 d4T-based regimen  10 (13.9%) 19 (11.4%) 5 (8.7%) 0.361 
 Other first line regimen 1 (1.4%) 3 (1.8%) 2 (3.6%)   
 WHO stage        
  I/II 62 (86.1%) 144 (87.0%) 54 (94.6%) 0.601 
  III/IV 10 (13.9%) 23 (13.0%) 3 (5.4%)   
 CD4 count (cells/mm³)     
 < 50 11 (15.2%) 17 (10.1%) 9 (16.3%)   
 51-100 12 (16.6%) 21 (12.5%) 5 (7.2%) 0.583 
 101-200 17 (23.6%) 41 (24.5%) 14 (25.4%)   
 201-350 26 (36.1%) 73 (43.7%) 22 (40.0%)   
 > 350 6 (8.3%) 15 (9.9%) 07 (10.9%)   
 
† VL: viral load. † TDF-based regimen: TDF-3TC/FTC-NVP/EFV. † d4T- based regimen: d4T -3TC/FTC-NVP/EFV  
† Other first line regimen: other first line regimen with neither TDF nor EFV. WHO: World Health Organization. 
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3.5 Comparison of demographic and clinical characteristics of 290 HIV-positive patients 
with detectable and undetectable viral load at 12 months 
 
 
Table 6 shows the distribution of the baseline demographic and clinical characteristics by 
plasma viral load status at 12 months. Of the total of 290 patients that completed the 12-month 
visit, 119 (41.0%) had their plasma viral load assessed and of these, 28.5% did not achieve an 
undetectable viral load (HIV/RNA ≥ 400 copies/ml) at 12 months.  
 
- Comparison of demographic characteristics at 12 months 
Table 6 shows that the distribution of the baseline demographics and clinical characteristics 
were similar between the two groups (p ≥ 0.05).  Among patients with a detectable plasma viral 
load at 12 months nearly 62.0% were females and there was a similar pattern among those with 
an undetectable plasma viral load at 12 months. However, the percentage of patients that 
reached secondary school is slightly higher in the group that suppressed the viral load at 12 
months compared to those with detectable viral load.  
 
- Comparison of clinical characteristics at 12 months 
 
Similarly, the distribution of clinical characteristics across the two groups is nearly identical. 
Of the total of 119 individuals with a detectable viral load at 12 months, most (85.0%) of them 
initiated on a TDF-based regimen. The proportion of patients who initiated a d4T-based 
regimen is the same (11.7%) in both groups. The distribution of CD4+ count was nearly 
identical across the two groups and among patients with a detectable viral load at 12 months 
87.0% were WHO stage I or II while in the other group this proportion was 82.3 
 
 
   
43 
 
Table 6 Comparison of demographic and clinical characteristics of 290 HIV-infected 
patients with detectable and undetectable viral load at 12 months. 
  VL at 12 months 
No VL at 12 
months 
  
Variables 
VL ≥ 400  
(n = 34) 
VL < 400 
(n = 85) 
        (n = 171) p value     
 Age                           
 > 35 years old 18 (52.9%) 
51 
(60.0%) 
106 (38.1%) 
0.490 
 ≤ 35 years old 16 (47.1%) 
34 
(40.0%) 
65 (61.9%) 
 Sex       
 Male 13 (38.2%) 
28 
(32.9%) 
60 (35.1%) 
0.911 
 Female 21 (61.8%) 
57 
(67.1%) 
111 (64.9%) 
 Education   
 
   
 Beyond secondary   school 5 (14.7%) 6 (7.1%) 3 (1.8%)   
 Secondary school 19 (55.8%) 
63 
(75.0%) 
123 (75.4%) 0.006 
 Primary school 5 (14.7%) 8 (9.5%) 9 (5.5%)   
 Illiterate/Not yet schooled 2 (5.8%) 3 (3.6%) 6 (3.7%)   
 Unknown 3 (8.8%) 4 (4.8%) 22 (13.5%)   
 Unemployment        
 Yes  10 (29.4%) 
36 
(42.4%) 
142 (82.1%) 0.990 
 No 24 (70.6%) 
49 
(57.6%) 
29 (19.9%) 
  
 Nationality        
 South African  28 (84.9%) 
79 
(92.9%) 
142 (83.0%) 0.060 
 Non-South African 5 (15.1%) 6 (7.1%) 29 (19.9%)   
 ART regimen at initiation      
 TDF-based regimen  30 (88.3%) 7 (87.6%) 150 (87.7%)   
 d4T-based regimen  4 (11.7%) 
10 
(11.7%) 
18 (10.5%) 0.770 
 Other first line regimen 0 (0%) 1 (1.8%) 3 (1.7%)   
 WHO stage        
  I/II 28 (82.3%) 
74 
(87.0%) 
161 (94.2%) 0.871 
  III/IV 6 (17.7%) 
11 
(13.0%) 
8 (5.8%) 
  
 CD4 count (cells/ mm³)     
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† VL: viral load. † TDF-based regimen: TDF-3TC/FTC-NVP/EFV. † D4T-based regimen: d4T -3TC/FTC-NVP/EFV † Other first line regimen: other 
first line regimen with neither TDF nor EFV.WHO: World Health Organization  
 
 
 
 
3.6 Description of the missing values in the LCM dataset  
 
Table 7 summarizes the availability of each predictor and outcome at 6 and 12 months. 
 
- Missing values at 6 months 
 At 6 months, missing values were present for all laboratory clinical markers as well as the self-
reported adherence variables and the plasma viral load. In all the predictors and adherence 
questionnaire variables, nearly 35% of data were missing at 6 months. Regarding the outcome 
of viral load, 241 observations were recorded and 55 values (18.6%) were missing at 6 months.  
- Missing values at 12 months 
At 12 months of follow up, out of the 290 patients, 165 (57%) values were missing for the 
outcome viral load. For the clinical and laboratory markers, of a total of 290 observations, 47 
(16.2%) values were missing for each 6-month follow-up variable in the dataset. Missing 
values were also present for the self-reported adherence variables (VAS, SMAQ, multi-method 
approach): out of the 290 patients at 12 months 47 missing values were present in each of the 
5 adherence parameters (VAS, self-report, pill identification test, multi-method approach of 
adherence, SMAQ).  
 < 50 5 (14.7%) 
12 
(14.2%) 
17 (10.3%) 
  
 51-100 5 (14.7%) 8 (9.4%) 25 (14.6%) 0.211 
 101-200 6 (17.6%) 
21 
(24.7%) 
44 (25.7%) 
  
 201-350 13 (38.2%) 
33 
(38.2%) 
73 (42.7%) 
  
 > 350 5 (14.7%) 
11 
(12.9%) 
11 (6.4%)   
   
45 
 
Table 7 Description of the missing values in the LCM dataset at 6 and at 12 months 
 At 6 months At 12 months 
Variables           Observed Missing (%)          Observed     Missing (%) 
Clinical and 
laboratory markers  
  
  
 
     
Body mass Index  190 106 (35%) 243 47 (16.2%) 
Haemoglobin 195 101 (34%) 243 47 (16.2%) 
CD4 count  195 101 (34%) 243 47 (16.2%) 
Total lymphocyte count  195 101 (34%) 243 47 (16.2%) 
Platelet count  192 104 (35%) 242 48 (16.5%) 
Mean cell volume 
(MCV)   
195 101 (34%) 243 47 (16.2%) 
Albumin decreased or 
unchanged  
192   102 (34%) 243 47 (16.2%)  
MCH  194 101 (34%) 243 47 (16.2%) 
Missing ARV visits 296 0 (0%) 290 0 (0%) 
Self-reported 
adherence   
        
VAS 195 101 (34%) 243 47 (16.2%) 
Self-report 194 102 (34%) 243 47 (16.2%) 
PIT 190 106 (35%) 243 47 (16.2%) 
Multi-method approach  195  101 (34.1%) 243 47 (16.2%) 
SMAQ 195 101 (34.1%) 243 47 (16.2%) 
Outcome          
Viral load   239 57 (19.3%) 119 171 (59%)  
 
†VAS: Visual Analog Scale; †PIT: Pill identification test; †SMAQ: Simplified Medication 
Adherence Questionnaire. MCH: Mean Corpuscular Haemoglobin. LCM: Low Cost Monitoring 
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3.7 Complete case analysis 
  
In this section, we present the results of the complete case analysis. If the outcome was missing, 
the patient was excluded from the analysis. In an inferential study, a complete case analysis 
has relatively low power. Therefore, we later used a multiple imputation technique to fill in 
missing values and perform a sensitivity analysis to compare our result with those obtained 
from a multiple imputed dataset.  
At 6 months of ART, out of the 296 patients, 239 had their plasma viral load assessed. At 12 
months of ART therapy, of 290 patients, 119 had plasma viral load assessed.  
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OBJECTIVE 2 
 
To determine the association between (i) self-reported adherence measures, (ii) CD4 response, (iii) 
MCV response, (iv) missed appointment, (v) new condition symptom (and a detectable viral load 
(≥ 400 copies/ml) at 6 and 12 months after ART initiation. 
 
3.7.1 Self-reported adherence at 6 and 12 months of ART therapy 
Table 8 summarizes the results of different methods of adherence assessment. For each method, 
the percentage of adherent or non-adherent patients is determined based on the total number of 
responses recorded and missing values are not included.  
 
- Self-reported adherence at 6 months  
At 6 months, of a total of 195 patients that were assessed by the visual analogue scale test, most 
of them (86.7%) had a score value greater than or equal to 95.0 %, 11 (5.6 %) had a score value 
below 75% and 15 (7.7%) had a score value ranging from 75.0 % to 94.0 %. In the multi-method 
approach which combines visual analogue scale, self-reporting and pill identification test, of a total 
of 195 patients, 86.7% were classified as being highly adherent, 23 (11.8%) were moderately 
adherent and 3 (1.5%) patients had low adherence. However, when the Simplified Medication 
Adherence Questionnaire (SMAQ) was used, the proportion of patients classified as being highly 
adherent decreased to 78.5%. 
 
- Self-reported adherence at 12 months  
At 12 months, of a total of 243 patients, 67.0% showed high adherence with the VAS ≥ 95%, 62 
(25.5%) were classified as being moderately adherent, and 23 (14.2%) were classified as poorly 
adherent. With the multi-method approach, the proportion of patients classified as highly adherent 
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decreased to nearly 60.0%. Like the 6-month results, at 12 months, when the SMAQ was used, the 
proportion of patients being classified as highly adherent decreased to 60.0%. Thus, based on the 
results of the self-reported adherence, most of the patients were highly adherent to their ARV drug 
regimen. However, care should be exercised in the interpretation of these results as there was a 
significant amount of missing data. 
Table 8 Self-reported adherence at 6 and at 12 months on ART. 
  
 
At 6 months                         At 12 months   
Self-reported adherence 
Total response 
(N=195) 
Percentage (%)  
Total response 
(N=243) 
Percentage (%)  
VAS      
95% or more  169 86.7% 153 67.0% 
75–94% 15 7.7% 57 23.0% 
Less than 75%  11 5.6% 33 10.0% 
Data missing  101 34.1% 47 16.0% 
Self-report 
 
 
 
  
High adherence  190 98.9% 242 99.5% 
Moderate adherence 2 1.0% 0 00.0% 
Poorly adherent  2 1.0% 1 0.5% 
Data missing  102 34.5% 47 16.0% 
PIT  
 
   
Knows the name 193 98.9% 243 100% 
Knows the number of pill per dose  188 98.9% 243 100% 
Knows the time the medication is 
taken 
188 98.9% 243 100% 
Data missing 106 35.8% 47 16.0% 
Multi-method Approach   
 
   
High adherence  169 86.7% 158 60.5% 
Moderate adherence 23 11.8% 62 25.5% 
Low adherence  3 1.5% 23 14.0% 
Data missing  101 34.1% 47 16.0% 
SMAQ     
Positive adherent 153 78.5% 154 63.0% 
Non-adherent 42 21.5% 89 37.0% 
Data missing 101 34.1% 47 16.0% 
VAS: Visual Analogue Scale, †PIT: Pill identification test; †SMAQ: Simplified Medication Adherence Questionnaire 
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3.7.2 Comparison of the result of self-reported between patients between with detectable 
viral load and patients with undetectable viral load. 
Table 9 shows the comparison of the results of the self-reported adherence between patients 
with and without undetectable viral load. To determine which measure of adherence is 
associated with a detectable viral load, the responses were transformed into binary variables. 
From the 2x2 table, the sensitivity, specificity, PPV and NPV of each self-reported adherence 
method was also estimated.  Although, the results were not globally significant, a low scale on 
the VAS or any other self-reported measure was associated with having a detectable viral load.  
 
3.7.3 Comparison of the result of self-reported adherence between patients with and 
with undetectable viral load at 6 months. 
At 6 months, a total of 163 patients had a measure of self-reported adherence (VAS, SMAQ, 
multi-approach method). Patients with detectable viral load demonstrated lower adherence 
with the VAS tool. When the multi-method approach method which combines VAS, PIT and 
self-reporting was used, there was a larger proportion of non-adherence with those with 
detectable viral load than those with undetectable viral load. Similarly, when the SMAQ tool 
was used to assess adherence, there was a large difference in patients with detectable viral load 
compared to those with undetectable viral load.     
 
3.7.4 Comparison of the result of self-reported adherence between patients with 
detectable and patients with undetectable viral load at 12 months. 
At 12 months, a total of 106 patients had a measure of plasma viral load and were also assessed 
with the VAS.  A total of 100 patients had a measure of plasma viral load and were also assessed 
with the SMAQ. The results indicate that when VAS was used, patients with undetectable viral 
load at 12 months were slightly less-adherent than the group with undetectable viral load. 
Regarding the results of the multi-method approach at 12 months, patients with detectable viral 
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loads demonstrated a greater increase in non-adherence to ART compared to those with 
undetectable viral loads. Using the SMAQ tool, although this was not also statistically 
significant, there was also a greater increase in non-adherence amongst those with detectable 
viral load compared to those without detectable viral load.  
 
3.7.5 Crude and adjusted predictors of detectable viral load (n=163) at 6 months after 
ART initiation, using modified Poisson regression analysis. 
Table 9 indicates the performance of the final regression model with the case complete analysis. 
For each predictor, it shows the adjusted and the unadjusted relative risks considering the effect 
of other predictors in the final model. The statistical significance is assessed with the P value 
and 95% CI. 
 
 At 6 months’ follow up, 7 variables were associated in the final Poisson Regression Model 
after adjusting for gender and age although these variables were not significant. The variables 
that were significantly associated with a detectable viral load included missing at least two 
ARV visits by ≥ 7 days (aRR: 2.35 95% CI: 1.08- 5.11); platelet count < 150 cells/mm3 (aRR; 
2.73 95% CI: 1.04- 7.18) and VAS (aRR: 1.65 95% CI: 1.01- 2.71). The result shows that 
patients who missed two ARV visits within the first 6 months were two times more at risk for 
detectable viral load, holding all other variables constant. After adjustment for other variables 
effects, the final regression model showed that, in patients with a VAS score < 95%, the risk 
of detectable viral load was 65% higher than that of patients who scored 95% or more. The 
multivariate model showed no association between failing to increase CD4 count by ≥ 50 
cells/mm3 and having an absolute change in MCV < 14.5 fL at 6 months after ART initiation. 
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Table 9 Crude and adjusted predictors of detectable viral load at 6 months (n=163) after ART 
initiation using a modified Poisson regression analysis. 
                                                     Viral load ≥ 400 copies/ml   
Baseline characteristics   RR (95% CI) aRR  p value    Scorea 
Age      
≤ 35 years old  Reference    
> 35 years old  1.11 (0.74 -1.67) 1.07 (0.67 - 1.73)   0.751  +1 
Gender  
  
 
Female  Reference  
 
 
Male  1.34 (0.91 - 1.97) 1.46 (0.93 - 2.29) 0.098  +1 
Level of education      
Beyond secondary school Reference    
Secondary school 2.60 (1.00 -  6.00)    
Primary school 1.26 (0.50 -  2.60)    
Illiterate/Not yet schooled 1.51 (0.60 - 3.00)    
Unknown 1.80 (0.70 -  4.00)    
Unemployment      
Yes 1.00 (0.70 - 1.40)    
No  Reference    
Nationality      
South African  1.50 (0.70 - 2.70)    
Non-South African Reference    
Alcohol drinking      
Yes  1.20 (0.40 - 2.00)    
No  Reference    
Smoking      
Yes  1.25 (0.60 - 2.40)    
No Reference    
ART regimen initiation      
TDF-based regimen  Reference    
d4T-based regimen  1.00 (0.10 -  4.20)    
Other first line regimen  1.01 (0.05 -  1.50)     
WHO stage at ART initiation    +1 
I/II Reference    
III/IV 1.00 (0.77 - 1.30) 1.10 (0.83 - 1.47)   
CD4 count at ART initiation (cells/mm3)    
<200 Reference    
200-350 0.78 (0.52 -  1.10)    
≥350 0.79 (0.26 -  0.44)    
BMI < 18.5 kg/m²   
 
 
Yes 1.08 (0.30 - 3.50)    
No Reference    
BMI drop from baseline > 2.5 kg/m²  
 
 
Yes 0.96 (0.60 -  1.50)    
No Reference    
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Hemoglobin drop from baseline ≥ 1g/dL    
Yes 0.60 (0.16 - 2.00)    
No Reference    
Failing to increase CD4 count by ≥ 50 cells/mm3    
Yes 0.85 (0.40 - 1.60) 0.78 (0.40 - 1.60) 0.611  
No Reference    
Total lymphocyte count < 2000 cells/mm3    
Yes 0.62 (0.40 - 1.10)    
No Reference    
Platelet count < 150 cells/mm³   +3 
Yes 2.24 (0.98 - 5.13) 2.73 (1.04 - 7.18) 0.041*  
No Reference    
MCV change < 14.5 fL   + 1 
Yes 1.23 (0.59 - 2.58) 1.31 (0.60 -2.89) 0.500  
No Reference    
Missing at least two ARV visits by ≥ 7 days    + 2 
Yes 1.68 (0.73 -3.85) 2.35 (1.08- 5.11)  0.030*  
No Reference    
VAS score test < 95%  
 
+2 
Yes 1.70 (1.03 - 2.81) 1.65 (1.01-2.71) 0.044*  
No Reference    
Multi-method approach    
 
 
Yes 1.50 (0.80 - 2.50)  
 
 
No Reference    
SMAQ  
 
 
Yes 1.20 (0.70 - 2.20)  
 
 
No Reference    
Serum lactate ≤ 2 mmol/L     
Yes 1.07 (0.70 - 1.50)    
No                                                                                                 Reference   
 
a The score calculated as the sum of the adjusted relative risks divided by the smallest regression coefficient and the result multiplied by 10 for each 
predictor rounded to the nearest integer. 
RR: Relative risk. †aRR: adjusted relative risk.ARV: antiretroviral therapy. TDF: Tenofovir Fumarate. d4T: Stavudine. Other first line regimen: 
ZDV-EFV-3TC or TDF-3TC-AZT. †WHO: World Health Organization. BMI: body mass index. MCV: mean cell volume. MCH: mean corpuscular 
hemoglobin. ARV: antiretroviral. VAS: Visual analogue scale. SMAQ: Simplified Medication Adherence Questionnaire. WHO: World Health 
Organization. *Significant at the 0.05 level. 
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3.7.6 Crude and adjusted predictors of detectable viral load (n=142) at 12 months after 
ART initiation, using modified Poisson regression analysis 
 
 
Table 10 indicates the performance of the final regression model with the case complete 
analysis. For each predictor, it shows the adjusted and unadjusted relative risks, considering 
the effect of other predictors. The statistical significance is assessed with the p value and 95% 
CI. 
At 12 months of follow up, the finding shows a positive relationship between age group, 
unemployment, alcohol drinking on the one hand and adherence to ART regimen on the other 
as assessed by a HIV/RNA ≥ 400 copies/ml. Patients aged above 35 years are 0.86 times less 
likely to have a detectable viral load compared to patients under 35 years old. Also, those who 
are unemployed are 0.6 times less likely to have a detectable viral load compared to those who 
are employed. However, patients who used to drink alcohol are 1.8 times at risk of having a 
detectable viral load than patients who do not take alcohol.  
 
Among the clinical markers, the results did not reveal any difference between the biomarker 
change over the previous 6 months and an adherence to ART therapy as assessed by the viral 
load at 12 months. Similarly, after adjustment for other variables, the results did not show any 
difference between patients classified as non-adherent by the traditional methods of adherence 
and the other groups.  After 12 months, when the other variables are considered, having missed 
more than two ARV visits was not associated with a detectable viral load. 
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Table 9 Crude and adjusted predictors of detectable viral load (n=142) at 12 months after ART 
initiation. 
                    Viral load ≥ 400 copies/ml`   
Baseline characteristics   RR (95% CI)  aRR (95% CI) 
p 
value* Scorea 
Age      
≤ 35 years old  Reference   +1 
> 35 years old  0.80 (0.50 - 1.50) 
0.49 (0.20 - 
0.90) 
0.027* 
 
Sex    
 +1 
Female  Reference    
Male  1.31 (0.70 - 2.20) 1.49 (0.70 - 3.0) 0.310  
Level of education      
Beyond secondary school Reference    
Secondary school 1.20 (0.30 - 3.70)    
Primary school 0.60 (0.20 - 1.70)    
Illiterate/Not yet schooled 1.00 (0.30 - 3.10)    
Unknown 1.10 (0.30 - 4.30)    
Unemployment      
Yes 0.60 (0.30 - 1.20) 
0.32 (0.10 - 
10.0) 
0.019* 
+0.5 
No  Reference    
Nationality      
South African  0.60 (0.30 - 1.30) 
0.77 (0.30 - 
1.70) 
0.540 
 
Non-South African Reference    
Alcohol drinking      
Yes  1.80 (0.70 - 4.20) 
3.08 (1.00 - 
9.30) 
0.045* 
+3 
No  Reference    
Smoking      
Yes  1.50 (0.60 - 3.80)    
No Reference    
ART regimen initiation      
TDF-based regimen  Reference    
d4T-based regimen  1.00 (0.40 - 2.40)    
Other first line regimen  1.01 (0.40 - 2.40)     
WHO stage at ART initiation    
I/II Reference    
III/IV 1.3 (0.60 - 2.60)    
CD4 count at ART initiation, cells/mm3    
<200 Reference    
200-350 0.80 (0.50 - 1.50)    
≥350 1.00 (0.40 - 2.30)    
BMI < 18.5 kg/m²   
 
 
Yes 1.05 (0.30 - 0.40)    
No Reference    
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BMI drop from baseline > 2.5 kg/m²    
Yes 1.2 (0.60 - 2.20)    
No Reference    
Hemoglobin drop from baseline ≥ 1g/dL    
Yes 1.50 (0.70 - 3.00)    
No Reference    
Failing to increase CD4 count by ≥ 50 cells/mm3    
Yes 1.10 (0.60 - 2.0)  0.611  
No Reference    
Total lymphocyte count < 2000 cells/mm3    
Yes 0.70 (0.30 - 1.40)    
No Reference    
Platelet count < 150 cells/mm³    
Yes 1.45 (0.40 - 6.00)  0.041* +1 
No Reference    
Absolute MCV change < 14.5 fL    
Yes 2.60 (0.70 - 9.00) 
2.70 (0.80 - 
9.10) 
0.110 
+2 
No Reference    
Albumin decreased or unchanged (g/dL)     
Yes 1.75 (0.87 - 3.00)    
No Reference    
MCH < 2.7 pg. after 6 months    
Yes 0.60 (0.20 - 2.40)    
No Reference    
Missing at least two ARV by ≥ 7 days    
Yes 1.20 (0.40 - 3.10)    
No Reference    
Change to VAS score test < 95%  
 
 
Yes 1.04 (0.60 - 1.80)    
No Reference    
Multi-method approach   
 
 
Yes 1.20 (0.07 - 2.00)    
No Reference    
SMAQ    
Yes 1.20 (0.70 - 2.10)    
No Reference    
Poor self-reported adherence at 6 months     
Yes        2.67 (1.20 - 7.00)                         2.10 (0.70 - 5.90) 
0.181  
No                                                                                                 Reference Reference   
 
as the score calculated as the sum of the adjusted relative risks divided by the smallest regression coefficient and the result multiplied by 10 for each 
predictor rounded to the nearest integer. 
RR: Relative risk. †aRR: adjusted relative risk. ART: antiretroviral therapy. TDF: Tenofovir Fumarate. d4T: Stavudine. Other first line regimen: ZDV-
EFV-3TC or TDF-3TC-AZT. †WHO: World Health Organization. BMI: Body mass index. MCV: mean cell volume. MCH: mean corpuscular 
hemoglobin. ARV: antiretroviral. VAS: Visual analogue scale. SMAQ: Simplified Medication Adherence Questionnaire. WHO: World Health 
Organization. *Significant at the 0.05 level. 
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OBJECTIVE 3 
To determine the diagnostic accuracy (sensitivity, specificity, PPV, NPV) of self-reported 
adherence (e.g. VAS, SMAQ or multi-method) and the composite marker including CD4 
response, MCV response, missed appointment and new condition or symptom compared to 
viral load as gold standard. 
3.7.7 Sensitivity, specificity, PPV and NPV of the self-reported measures of predicting 
adherence to ART compared to reference standards of viral loadTable 10 shows the ability 
of each self-reported adherence measure to correctly classify patients into two groups (adherent 
and non-adherent) as compared to viral load and by using two parameters at 6 and 12 months: 
sensitivity and specificity.  
 
- Sensitivity, specificity, PPV and NPV of the self-reported measures of predicting 
adherence to ART compared to the reference standard of viral load at 6 months 
 
During the first 6 months on ART, of the 49 patients who had a detectable viral load, 12 were 
correctly classified as such by the visual analogue scale, giving a sensitivity of 24%, this 
proportion was 26.0% and 18.0% for the SMAQ, and the multi-method tool respectively. In 
contrast, 100 of 114 patients who did not have a detectable viral load were classified as negative 
by the VAS, giving a specificity of 87.0%. This proportion was almost the same with the multi-
method approach (Se: 86.0%) but decreased to 79.0% for the SMAQ tool. Of the 46 HIV-
infected patients classified as non-adherent by the VAS tool, 12 were confirmed by the viral 
load, giving a PPV of 46.0% while the NPV increased to 73.0%. The PPV was 37.0% and 
35.0% for the multi-method approach and the SMAQ respectively while the NPV for both 
measures were similar at 71.0%. 
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- Sensitivity, specificity, PPV and NPV of the self-reported measures of predicting 
adherence to ART compared to the reference standard of viral load at 12 months 
 
At 12 months, for each of the 3 self-reported measures, the sensitivity and the PPV decreased 
while the specificity and the NPV increased. The sensitivity of the VAS was 37.0% while its 
specificity was 61.0%. The PPV and NPV for the VAS were 27.0% and 71.0% respectively. 
When the SMAQ was used, the four parameters were like the values obtained with the VAS 
tool (Se: 37.0%, Sp: 61.0%, PPV: 27.0%, NPV: 71.0%). Similarly, when VAS was combined 
with PIT and self-reporting into the multi-method approach, sensitivity was almost the same at 
36.0% but the specificity decreased to 62.0%. 
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Table 10 Comparison of the results of self-reported adherence between HIV-positive patients with detectable and undetectable viral load. 
                
 
 
 
 
 
 
       
Self-reported adherence   Se % Sp% PPV % NPV % 
  VL≥ 400 (n=49) VL < 400 (n=114)  (95% CI) (95% CI) (95%CI) (95%CI) 
         
At 6 months             
Non-adherent 12 (24.5%) 14 (12.3%) 
24 (17 - 31) 87 (82 - 92) 46 (38 - 53) 73 (66 - 98) 
Adherent 37 (75.5%) 100 (87.7%) 
Multi-method   
 
    
Non-adherent 9 (18.3%) 15 (13.2%) 
18 (12 - 24) 86 (81 - 92) 37 (30 -  44) 71 (64 - 78) 
Adherent 40 (81.7%) 99 (86.8%) 
SMAQ   
 
    
Non-adherent 13 (26.0%) 24 (21.0%) 
26 (19 - 33) 79 (72 - 85) 35 (27 -  42) 71 (64 - 78) 
Adherent 36 (73.0%) 90 (79.0%) 
At 12 months         
Non-adherent 12 (34.3%) 24 (33.8%) 
37 (28 - 47) 61 (56 - 75) 27 (25 -  43) 71 (60 - 80) 
Adherent 23 (65.7%) 47 (66.2%) 
Multi-method   
 
    
Non-adherent 20 (62.5%) 20 (29.4%) 
35 (28 - 47) 62 (61 - 79) 27 (28 -  47) 71 (61 - 80) 
Adherent 12 (37.5%) 48 (70.6%) 
SMAQ   
 
    
Non-adherent 12 (37.5%) 19 (27.9%) 
36 (28 - 47) 61 (63 - 80) 27 (29 -  48) 70 (62 - 80) 
Adherent 20 (62.5%) 49 (72.1%) 
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3.7.8 Comparison of changes in laboratory markers between HIV positive patients with 
and without detectable plasma viral load 
Table 11 shows a comparison of laboratory markers over 6 months by detectable plasma viral 
load at 6 or at 12 months of ART therapy. Overall results at 6 and 12 months show that globally 
there was no statistical association between laboratory marker changes and the outcome. 
However, these results must be interpreted with caution as there was a high number of missing 
values in both the predictors and the outcome. 
- Comparison of changes in laboratory markers between patients with and without a 
detectable plasma viral load at 6 months 
 
At 6 months, participants showed differences in total lymphocytes counts, CD4+ response at 6 
months and platelet count, however, these differences were not significant. Patients with 
undetectable viral load showed a higher proportion of individuals failing to achieve CD4 
increase ≥ 50 cells/mm3 by 6 months compared to those with a detectable viral load (20.0% 
vs.16.3% p = 0.741). Similarly, patients with detectable viral load showed lower proportion of 
individuals with a total lymphocyte count response < 2000 cells/mm3 (26.5% vs. 40.4% p = 
0.110) when compared to patients who did not suppress viral load during the first six months. 
Although not statistically significant with the complete dataset, there was a difference in 6-
month platelet count in patients with and without detectable viral load (2.8% vs. 0.6%, p = 
0.160).  
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Table 10 Changes in laboratory markers in patients and detectable viral load. 
                       HIV/RNA viral load (copies/ml) at 6 months      HIV/RNA viral load (copies/ml) at12 months 
Change over the previous 6 
months 
VL ≥ 400 
(n = 72) 
VL < 400 
(n = 167) 
p 
value* 
   VL ≥ 
400 
      (n = 
34) 
VL < 400 
(n = 85) 
p value* 
BMI < 18.5 kg/m²   
 
    
Yes  2 (4.16%) 4 (3.6%) 
0.710 
2 (6.5%) 4 (5.8%) 
0.910 
No 46 (95.8%) 106 (96.3%) 29 (93.5%) 64 (94.2%) 
BMI drop of > 2.5 kg/m²   
 
  
 
Yes  23 (50.0%) 57 (53.2%) 
0.710 
14 (58.3%) 23 (51.2%) 
0.600 
No 23 (50.0%) 50 (46.8%) 11 (41.7%) 23 (48.8%) 
Haemoglobin drop from 
baseline of ≥ 1 g/dl   
 
  
 
Yes  2 (4.1%) 9 (7.9%) 
0.371 
5 (16.0%) 5 (11.4%) 
0.300 
No 47 (95.9%) 105 (92.1%) 21 (84.0%) 42 (88.6%) 
CD4 count < 200 cells/mm³   
 
  
 
Yes  15 (30.0%) 23 (21.0%) 
0.290 
8 (21.8%) 8 (11.7%) 
0.110 
No 35 (70.0%) 91 (79.0%) 26 (78.2%) 63 (88.3%) 
Failing to achieve CD4 
increase ≥ 50 cells/mm³   
 
  
 
Yes  8 (16.3%) 21 (20.0%) 
0.741 
13 (52.0%) 21 (47.8%) 
0.820 
No 41 (83.7%) 93 (80.0%) 12 (48.0%) 23 (52.2%) 
Total lymphocyte count          
< 2000 cells/mm³   
 
  
 
Yes  13 (26.5%) 45 (40.4%) 
0.110 
22 (68.8%) 52 (73.5%) 
0.770 
No 36 (73.5%) 69 (59.6%) 10 (31.2%) 18 (26.5%) 
Platelet count < 150 cells 
/mm3   
 
  
 
Yes  2 (2.8%) 1 (0.6%) 
0.160 
1 (3.1%) 1 (1.5%) 
0.610 
No 70 (97.2%) 166 (99.4%) 31 (96.9%) 66 (98.5%) 
Mean cell volume < 150 fL   
 
  
 
Yes  37 (49.3%) 89 (53.3%) 
0.780 
24 (75.0%) 50 (73.0%)  
No 36 (50.7%) 78 (46.7%) 8 (25.0 %) 18 (17.0%) 0.840 
Absolute change in MCV < 
14.5 fL   
 
  
 
Yes  43 (87.7%) 96 (84.2%) 
0.550 
23 (92.0%) 33 (75.0%) 
0.091 
No 6 (12.2%) 18 (15.7%) 2 (8.0 %) 11 (25.0%) 
Albumin decreased or 
unchanged (g/dL) 
      
Yes  12 (24.5%) 28 (24.8%) 
0.961 
18 (72.0%) 22 (50.0%) 
0.070 
No 37 (73.5%) 85 (75.2%) 7 (18.0%) 22 (50.0%) 
MCH < 2.7 pg after 6 months    
 
  
 
Yes  1 (2.0%) 9 (7.9 %) 
0.151 
1 (3.2%) 7 (10.3%) 
0.490 
No 48 (98.0%) 105 (92.1%) 31 (96.8%) 61 (89.7%) 
Serum lactate ≥ 2 mmol/l       
Yes 38 (53.0%) 84 (51.0%) 0.710 13 (25.0%) 17 (12.0%) 0.710 
No 34 (47.0%) 83 (49.0%)  39 (75.0%) 120 (88.0)  
Missing at least 2 ARV visits 
≥ 7 days (%)   
 
  
 
Yes  3 (4.2%) 3 (1.8%) 
0.281 
3 (8.3%) 6 (6.7%) 
0.750 
No 69 (95.8%) 164 (98.2%) 33 (91.7%) 83 (93.3%) 
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- Comparison of changes in laboratory markers between patients with and without 
detectable plasma viral load at 12 months 
Table 11 shows a comparison of changes from 6 months to 12 months.  At 12 months, patients 
who failed to reach undetectable viral load had a lower increase in CD4 count (52.0% vs. 47.0% 
p = 0.82). There was also a greater drop from baseline (2.5 kg/m2) in BMI amongst those with 
detectable viral load compared to those without (58.0% vs 51.0% p = 0.506). Regarding MCV 
change from the previous 6 months, table 8 indicates that absolute change in MCV < 14.5 fL 
was higher in individuals with detectable viral load compared to those without (p = 0.091).  
3.7.9 Sensitivity, specificity, PPV and NPV of the laboratory markers for predicting 
adherence to ART compared to reference standard of viral load 
Table 12 indicates the diagnostic accuracy of each laboratory marker to correctly classify 
patients as adherent or non-adherent when compared to viral load. For each biomarker, the 
table indicates the observed sensitivity, specificity, positive and negative predictive value 
compared to reference standard of viral load. 
 
- Sensitivity, specificity, PPV and NPV of the laboratory markers for predicting 
adherence to ART compared to reference standard of viral load at 6 months 
 
At 6 months, platelet count used alone showed the highest sensitivity. When platelet count < 
100 fL was used as an indicator to classify patients as adherent or non-adherent, the sensitivity 
was 67.0%, while the specificity was 68.0%. Table 12 shows that when a BMI drop from 
baseline was used as a cut-off, the sensitivity decreased to 33.3%, the specificity was 69.7% 
and the PPV and NPV were 4.2% and 96.3% respectively. However, when failing to increase 
CD4 count ≥ 50 cells/mm3 was used as single indicator for adherence to ARV treatment, the 
sensitivity decreased to 21.0% and the specificity was 65.0%. When change in MCV <14.5 fL 
was used as cut-off to assess adherence to ART at 6 months after ART initiation, the sensitivity 
was 31.5% and the specificity was 80%. 
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- Sensitivity, specificity, PPV and NPV of laboratory markers for predicting 
adherence to ART compared to reference standard of viral load at 12 months 
 
At 12 months, MCV alone demonstrated the highest sensitivity. When mean cell volume   
< 150 fL after 12 months was used as a cut-off, the sensitivity was 73.0% and the specificity 
29.0% while the sensitivity and the specificity of a cut-off based on absolute change in MCV 
< 14.5 fL were 87.0% and 17.0% respectively. At 12 months after ART initiation, when drop 
in BMI > 2.5 kg/m2 was used as a cut-off to classify patient as being adherent or non-adherent, 
the sensitivity was 51.0% while the specificity was 60.0%. When failing to increase CD4 count 
by ≥ 50 cells/mm3 was used, the sensitivity increased to 55.0% while the specificity decreased 
to 52.0%. 
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Table 11 Sensitivity, Specificity, PPV and NPV of the changes in laboratory markers for predicting adherence to ART compared with viral load. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
†Se: sensitivity. Sp: specificity. PPV: positive predictive value. NPV: negative predictive value 
 BMI: body mass index.MCV: mean cell volume. MCH: mean corpuscular hemoglobin. ARV: antiretroviral. VAS: Visual analogue scale.  
SMAQ: Simplified Medication Adherence Questionnaire. 
  At 6 months At 12 months 
Predictors Se Sp PPV NPV Se Sp PPV NPV 
Baseline demographics          
Age 63.0% 41.0% 32.0% 71.0% 62.0% 40.0% 31.0% 71.0% 
Sex 43.0% 68.0% 31.0% 73.00% 45.0% 68.0% 37.0% 37.0% 
Change over 6 months          
BMI <18.5 kg/m² 33.3% 69.7% 4.1% 96.3% 3.0% 97.0% 33.0% 71.0% 
BMI drop from baseline of > 2.5 kg/m² 28.7% 68.5% 50.0% 46.2% 51.0% 60.0% 34.0% 75.0% 
Haemoglobin drop of ≥ 1g/dL 18.8% 69.0% 4.0% 92.0% 15.0% 91.0% 40.0% 73.0% 
Failing to increase CD4 count by ≥ 50 cells/mm3        
28.3% 
79.0%    16.0% 81.6% - - - - 
Failing to increase CD4 count by ≥ 100 cells/mm3        -      - - - 64.0% 27.2% 33.3% 57.1% 
Total lymphocyte count < 2000 cells/mm³ 21.0% 65.0% 26.0% 60.0% 37.0% 55.0% 24.0% 69.0% 
Platelet count < 150 cells/mm³ 67.0% 68.0% 2.0% 99.0% 00.0% 96.0% 00.0% 70.0% 
Mean cell volume < 150 fL   29.3% 69.0% 51.4% 46.7% 73.0% 29.0% 29.0% 73.0% 
Change in MCV < 14.5 fL 31.4% 80.0% 91.0% 14.4% 87.0% 17.0% 29.0% 78.0% 
MCH < 2.7 pg.   10.0% 68.0% 2.0% 92.0% 7.0% 91.0% 25.0% 71.0% 
Albumin decreased or unchanged (g/dL)         24.5%                                                           75.2% 30.0% 70.0% 53.0% 49.0% 21.0%      73.0% 
Serum lactate ≥ 2 mmol/L 53.0% 49.0% 31.0% 71.0% 27.0% 87.0% 43.7%   75.0% 
Missing at least 2 ARV visits by ≥ 7 days 4.0% 98.0% 50.0% 69.0% 5.0% 91.0% 22.0%   69.0% 
Self-reported adherence           
VAS 24.0% 87.0% 46.0% 73.0% 37.0% 61.0% 27.0% 71.0% 
SMAQ 26.0% 79.0% 35.0% 71.0% 36.0% 61.0% 27.0% 71.0% 
Multi-method approach 18.0% 86.0% 37.0% 71.0% 35.0% 62.5% 27.0%  70.8% 
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3.7.10 Risk scoring from the multivariate model for predicting a detectable viral load at 
6 and 12 months 
In this section, we used the result of the multivariate regression model to develop a diagnostic 
risk score to predict adherence to antiretroviral treatment. The Spiegelhalter and Knill-Jones 
approach was used to generate a scoring risk score (Seymour et al, 1990).  
Summing up the risk score for each patient gave the total predicted score of adherence to ART 
at 6 or 12 months. At 6 months, the diagnostic risk score included ART initiation variables 
(age, gender, WHO stage) added to clinical follow-up variables and self-reported adherence 
measures such as VAS < 95%, platelet count < 150 cells/mm3, absolute MCV change < 14.5 
fL Additionally, the diagnostic risk score included the variable missing at least 2 medical or 
ARV visits. Platelet count had a score of +3 and missed ARV visits and VAS < 95% had a 
score of +2. All other variables had a score of +1. At 6 months, the total predicted risk score 
ranged from 0 to 12. 
At 12 months, the diagnostic risk score included ART initiation variables such as age, gender 
and unemployment, alcohol drinking and platelet count as well as absolute MCV change < 14.5 
fL. Additionally, the diagnostic risk score included poor self-reported adherence on ART at 6 
months as assessed by viral load measure. At 12 months, the total predicted risk score for each 
patient ranged from 0 to 8.   
3.7.11 Diagnostic accuracy of the risk scoring and the self-reported methods to detect 
viral load in patients at the Themba Lethu Clinic 
In this section, we summarize the performance of the diagnostic risk score as well as of each 
adherence tool at 6 and 12 months.  Figure 3 and 4 indicate the diagnostic value of the 
diagnostic risk score derived from the multivariate model (A), the VAS tool (B), the SMAQ 
(C) and the multi-method tool (D), at 6 and 12 months over a whole range of possible cut-offs 
for classifying individuals as patients with good or poor adherence. The AUC represents the 
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probability that test results from randomly selected pairs of diseased and non-diseased are 
correctly classified (Bamber, 1975; Handley & McNeil, 1982). With a perfect discriminant test, 
the ROC curve is more to the upper left corner and had a value AUC equal or close to 1, while 
an uninformative diagnostic tool, will have an AUC ≤ 0.5.  
 
At the 6-month follow-up visit, the ROC curve for the total diagnostic risk score (Figure 3A) 
was more on the upper left corner than any other method and the AUC was calculated as 0.63 
(95% CI: 0.53-0.72). This AUC was higher than any of the self-reported adherence methods. 
The ROC curve for the visual analogue scale was less to the upper left corner as the AUC 
decreased to 0.56 (95% CI: 0.49-0.62) (Figure 3B). When using the SMAQ, the line of the 
ROC curve (Figure 3C) indicated an uninformative model as the AUC decreased to 0.52 (95% 
CI: 0.45-0.60). Similarly, the ROC curve was uninformative for the multi-method tool as the 
AUC also shifted to 0.52 (95% CI: 0.46-0.50) (Figure 3D). 
 
Figure 4 clearly shows that, at 12 months, the diagnostic risk score was uninformative as the 
ROC curve clearly falls below the discriminant threshold. 
 
At 12 months, the three self-reported adherence methods (VAS, SMAQ, multi-method tool) 
(Figure 4B, Figure 4C, Figure 4D) performed better than the diagnostic risk score Figure 4A 
to classify patients as being adherent or non-adherent. Therefore, at 12 months we did not 
assess the optimal cut-off value for the diagnostic risk score method. At 12 months, the AUC 
of the total diagnostic risk score was calculated as 0.44 (95% CI: 0.40-0.60) (Figure 4). When 
the three self-reported adherence methods were used, the AUC of the self-reported adherence 
measures was 0.48 (95% CI: 0.40-0.60), 0.51 (95% CI: 0.40-0.60) and 0.50 (95% CI: 0.41-
0.59) for the VAS, SMAQ and multi-method approach respectively. Similarly, Table 13 
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summarizes and compares the AUC of the different adherence methods when compared to viral 
load as the gold standard.  
 
Figure 2 ROC curve for the calculated diagnostic risk score, the VAS, the SMAQ and the 
multiple approach method at 6 months. 
 
Figure 3 ROC curve for the calculated diagnostic risk score, the VAS, the SMAQ and the 
multiple approach method at 12 months. 
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Table 13 AUC ROC curve for the diagnostic risk score and for the self-reported adherence measure 
among those with a viral load at 6 months. 
 
Method of adherence assessment 
 
 
Number  
 
 
AUC 
 
 
95% CI 
 
At 6 months of ART therapy        
Risk score at 6 months 163 0.63 0.53 - 0.72 
Visual analogue scale 163 0.55 0.49 - 0.62 
SMAQ 163 0.52 0.45 - 0.60 
Multi-method approach 163 0.53 0.46 - 0.58 
At 12 months of ART therapy       
Risk score at 12 months 142 0.44 0.40 - 0.60 
Visual analogue scale 142 0.48 0.40 - 0.60 
SMAQ 142  0.51 0.40 - 0.60 
Multi-method approach 142 0.50      0.41- 0.59 
 
*AUC: Area under curve. *SMAQ: Simplified Medication Adherence Questionnaire * ART: antiretroviral therapy 
 
3.7.12 Sensitivity, specificity, PPV and NPV of the diagnostic risk score at different cut-
off values compared to reference standard of viral load 
Table 14 shows the result of the assessment of the diagnostic accuracy of the 6-month 
diagnostic risk score to identify detectable viral load, defined by plasma viral load ≥ 400 
copies/ml. The sensitivity and specificity of the continuous risk score is defined at each cut-off 
point. The classification table shows 5 cut-off points derived from the continuous diagnostic 
risk score used to classify patients as positive or negative using the binary outcome viral load. 
Our result shows that for the cut-off point of ≥ 2 vs. < 2, of the 72 HIV-positive patients who 
truly had a detectable viral load at 6 months, 70 were correctly classified as such by the 
diagnostic risk score with a sensitivity of 97%, while of the 167 patients with undetectable viral 
load, 162 was classified as such giving specificity of 3%.  Additionally, at the cut-off point of 
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≥ 2 vs. < 2, if the test was positive, the probability that HIV-infected patients was positive 
(PPV) with the viral load was only 30.2% while, if the test was negative, the probability of 
having an undetectable viral load was calculated as 71.4% (NPV 71.4%). At the cut-off point 
of ≥ 3 vs. < 3, the sensitivity of the continuous risk score decreased to 89% but the specificity 
increased to 14.3% while the PPV and the NPV was almost the same as that of ≥ 2 vs. < 2.   
The optimal diagnostic accuracy was obtained at the cut-off points of 5 followed by the cut-off 
point of 4. Using the cut-off point of 5 (≥ 5 vs. < 5), the sensitivity of the diagnostic risk score 
increased to 64% but the specificity increased also to 34.7%. Additionally, when using a cut-
off point of 4 (≥ 4 vs. < 4), the sensitivity was 76.4% while the specificity was 34.7%. At these 
two-cut off points, the sensitivity was higher, and the proportion of false positive tests 
decreased while the predictive values (PPV and NPV) remained almost the same than the 
previous cut-off points.
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Table 12 Diagnostic accuracy of the risk score at different cut-off points at 6 months after ART initiation.  
 
Se: Sensitivity, Sp: Specificity PPV: Positive Predictive Value. NPV: Negative Predictive Value. 1-specificity*: FPR or False Positive Result
 
 
Cut-off points  
Detectable 
viral load 
(n=72) 
Undetectable 
viral load 
(n=167) 
Se Sp 
1 
specificity* 
PPV  NPV  
Predicted probability ≥ 2 
  
 
 
97.2% 
 
 
3.0% 
 
 
0.97 
 
 
 
30.2% 
 
 
 
71.4% 
  
2 (28.5%) 5 (71.4%) 
Predicted probability < 2 70 (30.0%) 162 (70.0%) 
          
Predicted probability ≥ 3 64 (30.0%) 147 (70.0%) 
89.0% 14.0% 0.85 31.0% 75.0% 
Predicted probability < 3 8 (28.6%)    147 (71.4%) 
    
      
Predicted probability ≥ 4 
  
76.4% 34.0. % 0.65 33.0% 72.0% 
57 (33.0%) 116 (67.0%) 
Predicted probability < 4 15 (22.7%) 51 (77.2%) 
          
Predicted probability ≥ 5 47 (35.0%) 89 (65.0%) 
64.0% 50.0% 0.50 35.6% 75.0% 
Predicted probability < 5 25 (24.2%) 78 (75.8%) 
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3.7.13 Clinical usefulness of the diagnostic risk score in practice at 6 months 
 
More than half (57%) of patients had a risk score ≥ 5 while almost two thirds (75%) had a risk 
score ≥ 4. Our results indicate that having detectable viral load was more common among 
patients with a risk score ≥ 5 (35%, 47/136) compared to patients with a risk score < 5 (24%, 
25/103). Similarly, compared to patients with a risk score < 4 or a risk score < 3, patients with 
a risk score ≥ 4 or ≥ 3 had a higher proportion of detectable viral load with 33% (57/173) and 
30% (64/173) respectively. Additionally, our result indicates that using the diagnostic risk 
score derived from the multivariate model, the cut-off ≥ 5 will result in more individuals with 
detectable viral load being classified as patients with poor adherence compared to other 
possible cut-off values (cut-off ≥ 4, cut-off ≥ 3, and cut-off ≥ 2). 
 
Furthermore, Figure 5 and 6 also indicate how the 6-month clinical usefulness may be used in 
routine clinical practice to estimate the probability of poor adherence on ARV treatment so that 
a decision can be taken on the necessity of performing a viral load or not.  This decision support 
can be used at the cut-off score of 5 or 4.  
 
A patient with a total risk score ≥ 5 will be likely considered to be poorly adherent and will be 
referred for viral load testing. Among those patients referred for further testing, a viral load ≥ 
400 copies/ml will confirm the diagnosis. Therefore, those patients identified as poorly 
adherent will need to receive intensive support such as adherence counseling, therapeutic 
education or more frequent monitoring. However, when the risk score is below the cut–off 
score of 5 (< 5), the patients will be classified as having good adherence and no viral load 
testing is indicated. However, a reassessment of the risk score at the next medical visit to 
confirm the status of the patient is necessary.  
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In practice the application of the diagnostic risk score at this threshold of five (≥ 5 vs. < 5) 
means that among patients with good adherence, nearly 53% (89/167) of them will be classified 
as patients with poor adherence, thus they are false positive, while, among those classified as 
patients with good adherence (score <5), 35% (25/72) will have true poor adherence or false 
negative.  When a lower cut-off value of   4 (≥ 4 vs. < 4) is applied to increase the sensitivity 
(65% vs < 79%), and lower the specificity (46% vs. < 33%), the application of this algorithm 
could mean that nearly 70% (116/167) of patients with good adherence level will be classified 
as poorly adherent while the scoring system will miss nearly 21% (15/72)   of patients with 
good adherence. 
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Figure 4 Clinical usefulness of the diagnostic risk score in practice at 6 months with a cut-off 
value of 5. (TN True negative; TP True positive; FN False negative; FP False positive).  
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                                                                                            N=239 
 
 
 
 
 
 
 
 
 
 
Figure 5 Clinical usefulness of the diagnostic risk score in practice at 6 months with a cut-off 
value of 4. (TN True negative; TP True positive; FN False negative; FP False positive).  
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3.8 Sensitivity Analysis 
 
The presence of missing values threatens validity. Therefore, in this section, we explore the 
reason for missingness and use a multiple imputation technique to fill in all the missing values 
in the predictors and the outcomes at 6 and 12 months. We compared this approach to the 
complete case analysis method previously used. First, we used the observed data to explore the 
missingness mechanism by exploring the relation between missing data and observed values. 
Secondly, we assessed the impact of missing data on the estimates of the multivariate 
regression model at 6 and 12 months after ART initiation under the missing at random 
assumption (MAR).   
 
3.8.1 Relation between missingness of the demographic characteristics and the 
measured viral load at 6 and 12 months after ART initiation 
 
Table 15 provides a breakdown of the relation between the missingness of the predictor and a 
detectable viral load at 6 and 12 months using the observed dataset. The result indicates that 
missingness among the baseline demographic characteristics was minimal. In general, there 
was no relation between the missingness of the baseline demographic characteristics and the 
measured viral load at 6 or 12 months.  
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Table 13 Association between viral load detectable at 6 and at 12 months and missing values in 
baseline demographic characteristics. 
              
  Viral load at 6 months   
Viral load at 12 
months 
  
            
Demographic 
baseline 
VL ≥ 400   VL ˂ 400  
p value* 
 VL ≥ 
400 
VL˂ 400  
p value 
(n = 72)  (n = 167) (n = 34) (n = 85) 
Age         
Valid 72 (100%) 167 (100%)  34 85   
Missing 00 (00%) 00 (00%) 0.618 0 0 0.568 
Sex   
  
 
   
Valid  72 (100%) 167 (100%)  34 85   
Missing 00 (00%) 00 (00%) 0.618 0 0 0.568 
Education         
Valid 71(98.6%) 163 (97.6%) 
 
34 84   0.618 
Missing 1 (1.4%) 4 (2.4%)  1 0 0.328 
Unemployment         
Valid 72 (100%) 167 (100%) 0.618 34 85   
Missing 00 (00%) 00 (00%)  0 0 0.568 
Nationality         
Valid  
71 
(98.6%) 
      167 
(100%)           
0.127 33 85   
Missing 01 (1.4%) 00 (00%)  1 0 0.633 
Alcohol drinking         
Valid 
71 
(98.6%) 
167 (100%) 0.127 34 85   
Missing 1 (1.4%) 00 (00%)  0 0 0.633 
Smoking         
Valid 
71 
(98.6%) 
167 (00%) 0.127 34 85   
Missing 01 (1.4%) 00 (00%)   0 0 0.633 
 
* Significant at the 0.05 levels 
§. P value calculated using Pearson’s chi-square test or Fisher’s exact test where chi-square assumptions were not met. 
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3.8.2 Relation between missingness of clinical characteristics and detectable at viral load 
at 6 months 
Table 16 shows the proportion of detectable viral load by missing values on the clinical and 
laboratory markers at 6 months. There was no association between having a missing value in 
the clinical and laboratory markers at 6 months and a detectable viral load. For each clinical 
and laboratory marker, the proportion of HIV-infected patients with detectable viral load was 
lower in patients whose clinical or laboratory marker was missing. However, none of the 
association reported in the table 75 was statistically significant (p < 0.05). 
3.8.3 Relation between missingness of clinical characteristics and a detectable viral load 
at 12 months 
Table 16 shows the proportion of detectable viral load between individuals with and without 
missing values on the clinical and laboratory markers at 12 months after ART initiation.  
Similarly, according to the pattern observed for missing values at 6 months, there is no relation 
between the missing values and a detectable viral load at 12 months.  
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Table 14 Relation between missingness of clinical and laboratory markers and detectable viral load at 
6 and 12 months. 
  Viral load at 6 months   
Clinical and laboratory markers  
 VL ≥ 400   VL ˂ 400 
p value 
(n = 72) (n = 167) 
- At 6 months   
Body mass Index (kg/m2    
Valid  48 (66.7%) 110 (65.8%) 0.905 
Missing 24 (33.3%) 57 (34.2%)   
Haemoglobin(g/dL)  
   
Valid  49 (68.1%)  114 (68.3%) 0.975 
Missing 23 (31.9%) 53 (31.7%)   
CD4 count (cells/mm3)     
Valid  49 (68.1%)  114 (68.3% 0.975 
Missing 23 (31.9%)  53 (31.7%)   
Total lymphocyte count (cells/mm3)    
Valid  49 (68.1%) 114 (68.3%) 0.975 
Missing 23 (31.9%) 53 (31.7%)   
Platelet count cells/ mm3    
Valid  48 (66.7%) 113 (67.7%) 0.880 
Missing 24 (33.3%) 54 (33.3%)   
Mean cell volume (fL)    
Valid  49 (68.1%) 114 (68.3 %) 0.975 
Missing 23 (31.9%) 53 (31.7%)   
Albumin (d/dL)     
Valid  49 (68.1%)  113 (67.7%) 0.953 
Missing 23 (31.9% 54 (32.3%)   
MCH (pg.)     
Valid  49 (68.1%) 114 (68.3%) 0.975 
Missing 23 (31.9%) 53 (31.7%)   
Serum Lactate (mmol/l)     
Valid  46 (63.9%) 111 (66.5%) 0.700 
Missing 26 (36.1%) 57 (33.5%)   
Missing at least 2 ARV visits ≥7 days   
Valid  72 (100%) 167 (100%) -  
Missing 00 (00%) 00 (00%)   
VAS (%)     
Valid  49 (68.1%) 114 (68.3%) 0.975 
Missing 23 (31.9%)  53 (31.7%)        
Multi-method approach (Yes/No)    
Valid  49 (68.1%)  114 (68.3%) 0.975 
Missing 23 (31.9%)  53 (31.7%)        
SMAQ (Yes/No)     
Valid  49 (68.1%)  114 (68.3%) 0.975 
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Missing 23 (31.9%) 53 (31.7%)        
- At 12 months    
BMI (kg/m2)     
Valid  31(91.2%) 68 (80.0%)   
Missing 3 (8.8%) 17 (20.0%) 0.141 
Haemoglobin (g/dl)  
   
Valid  32 (94.2%) 68 (80.0%)   
Missing 2 (5.8%) 17 (20.0%) 0.058 
CD4 count (cells/mm3)    
Valid  32 (94.2%) 68 (80.0%)   
Missing 2 (5.8%) 17 (20.0%) 0.058 
Total lymphocyte count cells/mm3    
Valid  32 (94.2%) 68 (80.0%)   
Missing 2 (5.8%) 17 (20.0%) 0.058 
Platelet count (102/mm3)    
Valid  32 (94.2%) 68 (80.0%)   
Missing 2 (5.8%) 17 (20.0%) 0.058 
MCV (fL)     
Valid  32 (94.2%) 68(80.0%)   
Missing 2(5.8%) 17 (20.0%) 0.058 
Albumin (g/dL)     
Valid  32 (94.2%) 68 (80.0%)   
Missing 2 (5.8%) 17 (20%) 0.058 
MCH (pg)     
Valid  26 (76.5%) 53 (62.3%)   
Missing 8 (23.5%) 32 (37.6%) 0.141 
Serum lactate (mmol/L)    
Valid  30 (88.2%) 63 (74.0%) 0.092 
Missing 4 (11.8%) 22 (26.0%)   
Missing at least 2 ARV visits ≥7 days    
Valid  34 (100%) 85 (100%) 0.568  
Missing 00 (00.0%) 00 (00.0%)   
VAS (%)     
Valid  32 (94.0. %) 68 (80.0%)   
Missing 2 (6%) 17 (20%) 0.058  
Multi-method approach (Yes/No)    
Valid  32 (94.0. %) 68 (80.0%)   
Missing 2 (6.0%) 17 (20.0%) 0.058 
SMAQ (Yes/No)     
Valid  32 (94.0%) 68 (80.0%) 0.058  
Missing 2 (6.0%) 17 (20.0%)   
 
†BMI: body mass index. †MCV: mean cell volume. †MCH: mean corpuscular hemoglobin.  †VAS: Visual analogue scale. †SMAQ: Simplified 
Medication Adherence Questionnaire *Significant at 0.05 level 
†BMI: body mass index. †MCV: mean cell volume. †MCH: mean corpuscular hemoglobin.  †ARV: antiretroviral †VAS: Visual analogue scale. †SMAQ: 
Simplified Medication Adherence Questionnaire. 
*Significant at 0.05 level 
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3.8.5 Comparison of complete case analysis and imputed resssults 
 
There were no considerable differences in the results when comparing the complete case 
analysis to the imputed analysis although some minor similarities were noted. For this reason, 
we compared the results obtained from the case complete analysis with the results obtained 
from the multiple imputed dataset under the MAR assumption for estimation of predictors of 
detectable viral load.   
 
Table 17 indicates the effect of imputing the missing values in the outcome and the predictors 
on the LCM database and the performance of the diagnostic model using VL at 6 months as 
gold standard. The case complete analysis included 119 cases although there were 290 patients 
with the imputed dataset. The result in Table 18 displays the estimation of the adjusted relative 
risk with the final regression model to complete case analysis versus the final model fit to the 
imputed dataset under the missing at random assumption. In both models, the variables age 
(>35 years), gender, MCV change < 14.5 fL are not significantly associated with detectable 
viral load at 6 months. However, the largest standard errors are obtained more from the case 
complete case analysis.  In the case of the variables, VAS < 95%, platelet count < 150 
cells/mm3 and missing at least 2 ARV visits by more than 7 days, the adjusted relative risk was 
significant in the complete case analysis, whereas these variables were no longer significant 
with the imputed dataset. However, none of these variables were statistically significant. 
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Table 15 Results of the multiple imputation for estimation of the predictors of ART at 6 months after ART initiation. 
  Analysis with complete cases dataset Analysis with imputed dataset (k=10) 
Variables  RR  
Standard 
error  
P 
value 
RR 
Standard 
error  
P value  
Age category at ART initiation        
≤ 35 years old  Reference    Reference     
> 35 years old  1.1 (0.6 - 1.7) 0.328 0.752 1.1 (0.7 - 1.6) 0.221 0.380 
Gender        
Female Reference    Reference     
Male  1.46 (0.9 - 2.3) 0.931 0.098 1.2 (0.8 -1.8) 0.250 0.283 
VAS < 95%        
Yes 1.65 (1.01 - 2.71) 0.417 0.044* 1.4 (0.8 - 2.3) 0.342 0.193 
No Reference    Reference     
Platelet count < 150 cells/mm3       
Yes 2.73 (1.40 - 7.10) 1.346 0.041* 2.3 (1.0 - 5.2) 0.960 0.042 
No Reference    Reference     
Absolute change in MCV < 14.5 fL      
Yes 1.31 (0.60 - 2.90) 0.530 0.670 1.3 (0.6 - 3.1) 0.500 0.486 
No Reference    Reference     
Missing at least 2 ARV visits by ≥ 7 days       
Yes 2.40 (1.08 - 5.10) 0.937 0.030* 1.5 (0.6 - 4.1) 0.769 0.371 
No Reference    Reference     
Failing to increase CD4 count by ≥ 50 cells/mm3     
Yes 0.84 (0.45 - 1.60) 0.273 0.611 0.7 (0.3 - 2.3) 0.361 0.611 
No Reference    Reference     
WHO stage at ART initiation       
 I/II Reference    Reference     
III/V 1.10 (0.83 - 1.40 0.161 0.486 1 (0.7 -1.4) 0.146 0.740 
RR: relative risk
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Table 16 Results of the multiple imputation for estimation of the predictors of ART at 12 months after ART initiation. 
RR: relative risk
Variables  
 
RR  
Standard 
error  
 
p 
value 
RR   
Standard 
error  
P value  
    
Age category at initiation        
≤ 35 years old  Reference    Reference    
> 35 years old  0.6 (0.31 - 1.32) 0.234 0.237 0.8 (0.45 - 1.4) 0.231 0.489 
Gender       
Female Reference    Reference    
Male  0.9 (0.47 - 2.08) 0.371 0.977 0.9 (0.53 -1.6) 0.260 0.870 
Score at VAS < 95%       
Yes 0.9 (0.43 - 1.9) 0.325 0.809 1.1 (0.43 -2.78) 0.460 0.820 
No Reference    Reference    
Platelet count < 150 cells/mm3       
Yes       
No Reference    Reference    
Absolute change in MCV < 14.5 fL       
Yes 3.6 (0.68 - 18.97) 3.057 0.131 2.4 (0.55-11.01) 1.710 0.255 
No Reference    Reference    
Missing at least 2 ARV visits by ≥7 days      
Yes 0.9 (0.29 - 6.05) 1.231 0.960 1.3 (0.29 - 6.05) 0.950 0.681 
No Reference    Reference    
Failing to increase CD4 count by ≥ 50 
cells/mm3       
Yes       
No Reference    Reference    
 Self-reported adherence at 6 months       
Yes 2.1 (0.70 - 5.99) 1.120 0.188 3.1 (1.05 - 9.11) 1.528 0.041 
 No Reference    Reference    
       
   
82 
 
CHAPTER FOUR- DISCUSSION 
 
4.1 Introduction 
 
In line with the objectives and the study findings, this chapter gives a summary of the results 
and explores the scientific contribution of our study. The study limitations are discussed by 
identifying threat to validity and the generalizability of the results. Finally, the chapter gives 
an overview of the implications of our findings and the potential for further research in this 
area. 
4.2 Summary of results 
 
The study aimed to identify the usefulness of a composite marker of poor adherence assessed 
by failure to achieve virologic suppression which is defined as a plasma viral load ≥ 400 
copies/ml at 6 months on ART in patients on first-line regimen at Themba Lethu Clinic, in 
Johannesburg, South Africa. This is a secondary analysis of data prospectively collected from 
HIV-postive patients initiated onto standard government first-line ART regimen, from 
February 2010 to April 2014.  
At baseline, 353 patients were enrolled and the mean age at ART initiation was 37.2 years. 
Most of the patients (87.5%) initiated on a Tenofovir-based regimen. In terms of viral load 
suppression at 6 and 12 months, of 239 patients, 30% failed to suppress viral load (HIV/RNA 
≥ 400 copies/ml) by 6 months. Patients with undetectable plasma viral load during this period 
were more likely to be female, educated and older compared to those with detectable viral load.  
In terms of viral load suppression, at 12 months, of 119 patients, 28.5% did not supress viral 
load. Among them, more than half were female and the percentage of patients that reached 
secondary school was slightly higher in the group that suppressed viral load at 12 months 
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compared to those with detectable viral load. The distribution of CD4 count between the two 
groups was similar. 
 
To reduce sampling bias, we assessed how the patients in LCM cohort study should be 
adequately representative of the population of patients at TLC which are likely to receive the 
clinical prediction score (CPS). Therefore, we compared the demographic characteristics (age, 
sex), other medical conditions unrelated to the outcome at 6 and 12 months (Appendix E). Our 
results indicate that the baseline demographic characteristics of the patients who initiated ART 
were well balanced between the groups. Similarly, on the basis of clinical characteristics prior 
to ART initiation, the characteristics are nearly the same although there was less people with a 
CD4 count < 50 cells/mm3 in the LCM cohort database. 
 
Results of complete case analysis showed a consistent trend of patients having detectable viral 
load being classified as non-adherent with any of the self-reported adherence measures (albeit 
not statistically significant). Using viral load as gold standard, the analysis showed that all the 
three self-reported adherence measures (VAS, SMAQ, and multi-method approach) yielded a 
high proportion of false negative results during the first 6 and 12 months on ART. Adjusted 
multivariate modified Poisson regression model with robust variance estimates, showed that 
patients who missed at least two medical or ARV visits, had a platelet count < 100 fL and a 
visual analog scale < 95%, were at increased risk of failing to achieve viral load suppression 
by 6 months on ART.  At 12 months, only being older than 35 years, being unemployed and 
alcohol consumption were associated with failure to suppress viral load. The current ART 
regimen was not associated with failure to suppress viral load, neither at 6 nor at 12 months. 
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At 6 months of ART, the ROC curve of the continuous diagnostic risk score was more 
discriminant than any of the three self-reported adherence measures and different cut-off points 
yielded less false negative results when compared to viral load. Additionally, both self-reported 
adherence and risk scores derived from the multivariate model showed high negative predictive 
values during the first 6 months. However, at 12 months, the ROC curve based on the 
continuous diagnostic risk score was uninformative as the AUC was clearly below 0.5 while 
the self-reported adherence measures remained at the same levels. 
 
Our analysis of the missing data shows that the data are not missing for reasons related to the 
predictors or outcome values, thus the hypothesis that data are missing completely at random 
(MCAR) seems to be more probable although the missing not at random mechanism (MNAR) 
cannot be ruled out as we didn’t have the unobserved dataset. Sensitivity analysis under the 
MAR assumption did not show similar association, instead, the results showed notable 
difference between the models fit with CCA compared with model fit with imputed datasets. 
The findings from the case complete analysis takes priority over the estimation from multiple 
imputed dataset.  
 
 In conclusion, our results show that, during the first 6 months of ART, a combination of 
clinical information, laboratory data and self-reported adherence measures can be used to better 
monitor adherence instead of self-reported methods in patients on first-line regimens.  
 
4.3 Viral load suppression during the first 6 and 12 months on ART 
 
In the following sections, the study findings are compared with relevant knowledge, other 
findings from previous studies and possible explanations of our results. Furthermore, the 
chapter discusses the strengths and study limitations. 
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Of 239 patients, 72 (30.1%) did not achieve an undetectable viral load (HIV/RNA≥ 400 
copies/ml) at 6 months. At 12 months, 119 (41.0%) had their plasma viral load assessed and 
among them 28.5% did not achieve an undetectable viral load. Similar levels of viral load 
suppression in HIV-positive patients has been described by  Fox et al (2012) at Themba Lethu 
Clinic.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
In a meta-analysis study on the prevalence of viral suppression after 12 months of antiretroviral 
therapy in low and middle-income countries, McMahon et al, (2013) found that the proportion 
of patients showing viral suppression was 84.0%. Our results support findings from previous 
studies (Donnelly et al, 2005; Anastos et al, 1999; Sterling et al, 1999; Rezza et al, 2000) that 
demonstrated that viral load may varies by gender, race, age and probably depends on the mode 
of transmission. In a Italian cohort study, (Sterling et al, 1999) reported lower median plasma 
viral load in women added to the fact that viral load increased more rapidly overtime among 
HIV-positive women compared to HIV-positive men.  
 
4.4 Laboratory markers changes and viral load response 
 
- CD4 count response  
Our results showed that there was no association between baseline CD4 count and viral load 
suppression during the first 6 or 12 months of ART treatment. We also compared the change 
in CD4 count response between patients with and without viral load suppression. Although not 
statistically significant, patients who suppressed viral load were less likely to have a poor CD4 
response compared to patients who suppressed viral load during the first 6 months, while at 12 
months on ART, the reverse situation was observed. When “CD4 < 200 cells/mm3 was used as 
a cut-off point to assess adherence to ART compared to viral load as gold standard, the 
sensitivity and the specificity at 6 months were 28.6% and 78.9% respectively, while at 12 
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months, when “failure to increase by > 100 cells/mm3” was used, the sensitivity increased to 
64%.  
Our results confirm findings from previous studies  that  CD4 count response is a poor predictor 
of HIV treatment outcome in adult and children on antiretroviral therapy (Badri et al, 2008) 
(Moore et al,2008). Badri et al, (2008) showed that CD4 count changes was associated with 
viral load but may have a very limited utility in identifying virologic failure in individual 
patients. However, using routinely collected health data from South Africa, Evans et al (2014) 
showed that CD4 when combined with baseline and clinical information increased the 
sensitivity and specificity of a clinical prediction score (CPS) used to target viral load failure 
defined as two consecutive HIV-RNA (400 copies/ml) following suppression below this level 
(Evans et al, 2014).  
 
- Total lymphocyte count change  
Our 6 months analysis showed that HIV-positive patients with detectable viral load had greater 
absolute lymphocyte count response compared to individuals who suppressed viral load and 
the same trend was observed at 12 months after ART initiation. When an absolute lymphocyte 
count < 2000 cells/mm³ was used as cut-off point compared to viral load as gold standard, the 
sensitivity at 6 and 12 months was very low at only 21% and 37% respectively while the 
specificity was 65% and 55% respectively. This low diagnostic value of the TLC may be 
partially. Findings from previous studies (Schreibman & Friedland, 2004; Denue et al,2013; 
Lau et al, 2003) that showed that total lymphocyte count is not a proxy indicator of early viral 
load suppression, but rather a marker of prognosis and long term survival during HIV infection 
(Lau et al, 2003). Data from previous studies showed that total lymphocyte count is a marker 
of disease staging and opportunistic infection. A study by Schreibman  and Friedland (2004) 
conducted in 831 HIV-positive patients indicated that, when used as a surrogate marker of CD4 
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count, 98% of those with total lymphocyte count of < 1000 had a CD4 cell count < 200 and a 
specificity of 98%. However other studies have shown that no consensus cut-off point is 
actually found (Schreibman & Friedland, 2004) (Lau et al, 2003) 
 
- MCV change  
Several authors (Steele et al, 2002; Segeral et al, 2010; Cosby, 2007) have reported the effect 
of antiretroviral treatment on the haemoglobin level and macrocytosis defined as mean 
corpuscular volume (MCV) exceeding 100 fL. A Study from retrospective databases and 
prospective cohorts has provided evidence of a strong relationship between adherence to ART 
and MCV (Segeral et al, 2010). In contrast, our findings did not show any relation between 
MCV and viral load suppression at 6 or at 12 months. The absence of an association between 
macrocytosis as calculated by the MCV and the outcome may be explained by the fact that 
macrocytosis during ART is mainly observed in patients strictly adherent to AZT regimen and 
only partially in those receiving stavudine (d4T), another thymidine analogue. In our study, 
most of the patients (87.5%) were initiated on a TDF-based regimen. This is because in the 
2013 South African national treatment guidelines, the combination TDF+FTC/3TC+EFV/NVP 
is the first-line preferred regimen for all new patients needing treatment. Based on these 
guidelines, AZT is only used when there is contraindication to TDF such as renal diseases or 
the use of other nephrotoxic drugs (aminoglycosides) while d4T is only used when there is 
contraindication to TDF and AZT. Other factors that may have affected the association between 
MCV and detectable viral load in this study may be the smaller sample size and the fact that in 
our study we transformed the MCV variable from a continuous to a categorical variable.  
Regarding the diagnostic accuracy of MCV taken alone, although this variable was not 
significantly associated with viral load suppression during the first 6 or 12 months on ART, 
our results indicate that this biomarker has a highly discriminant value long-term. Using the 
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change in MCV < 14.5 fL as a cut-off value, the sensitivity was poor at 6 months (31.4%) but 
it increased to 80% at 12 months. However, the specificity of this biomarker remained poor at 
6 and 12 months. Our results seem to suggest that in the multifactorial nature of adherence to 
ART treatment, the discriminative utility of the MCV as a marker of viral load suppression is 
poor at 6 months but has a high discriminant value at 12 months. However, this situation may 
be explained by the fact that at 6 months we assessed the diagnostic accuracy of this biomarker 
with only incident cases whereas at 12 months we have HIV-positive patients who have been 
longer on ART (6 vs. 12 months). People who were diagnosed as having detectable viral load 
at 6 months may be more likely to die shorter before the 12 months follow-up. Therefore, the  
12 month’s prevalent cohort is more prone to survival bias which impacts on  the discriminative 
value  of the biomarker at 12 months (Miller et al, 2012). 
 
- Serum lactate  
In this study, we did not find a significant association between serum lactate and a detectable 
viral load at 6 or 12 months. Our findings did not confirm previous studies that suggest that an 
elevated serum lactate is associated with treatment with NRTI and an undetectable viral load. 
In their study among 251 HIV-positive patients in the US, Desai et al (2003) suggested that 
elevated lactate levels are useful in assessing adherence. They found that asymptomatic 
hyperlactatemia defined as a serum lactate concentration > 2mmol/L was associated with an 
undetectable viral load regardless of treatment regimen. The fact that asymptomatic 
hyperlactatemia occurs mostly on adult HIV-infected patients initiated with stavudine and 
didanosine may explain why we did not observe this. In our study, more than 75% of patients 
were initiated on TDF-based regimen. 
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- Platelet count response  
The present study showed a statistically significant association between platelet count and a 
detectable viral load. At 6 months, after adjustment for other variables effects, the final 
modified Poisson regression model showed that patients with platelet count < 150 cells/mm3 
were 2.7 times more likely to have a detectable viral load. However, this was not confirmed 
with the multivariate model at 6 months. At 6 months, platelet count used alone showed the 
highest sensitivity; when platelet count < 150 cells/mm3 was used as an indicator to classify a 
patient as adherent or non-adherent, the sensitivity was 67%, and the specificity 68%. This 
finding at 6 months is in line with another study by Zetterberg et al (2013). In their study, 
platelet counts were retrospectively collected from 2206 HIV-positive patients from visits at 
study entry and during follow-up. They reported that platelet count decreased significantly in 
interrupted-ARV groups while they remained stable in the group with viral suppression. 
However, the same study (Zetterberg et al, 2013) showed that the reintroduction of ARV 
therapy reversed the thrombocytopenia. Two factors may explain the effect of adherence to 
ART on the platelet: first the HIV replication itself and secondly the fact that platelet count is 
itself an inflammatory marker (Zetterberg et al, 2013) 
 
- Haemoglobin and Albumin levels changes  
Regarding the usefulness of haemoglobin and albumin as prognostic markers of detectable viral 
load or adherence to antiretroviral treatment, our study did not find any association between 
the 6 months changes of these biomarkers and having a detectable viral load at 6 or 12 months. 
However a study in India among 122 adults HIV-positive patients aimed at studying the 
usefulness of haemoglobin and albumin as prognostic markers for ART, the changes in 
haemoglobin and albumin levels increased after ART initiation and were found to be strong 
prognostic markers of HIV disease progression at pre-, one and two year post treatment 
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(Chauhan et al, 2011). Anaemia and hematologic disorders are the most frequent diseases in 
HIV-infected patients on antiretroviral treatment (De Santis et al, 2011). However, anaemia  is 
more related to disease progression or as an adverse event for patients who have been initiated 
on zidovudine based regimen (Cosby et al, 2007) (De Santis et al,2011) .  
 
- Body mass index and MCH changes 
Regarding the usefulness of body mass index (BMI) and MCH as possible diagnostic markers 
of failure to suppress viral load, our study did not find any association between the 6 months 
changes of these biomarkers and having a detectable viral load at 6 or 12 months. However, 
findings from other studies have found a positive correlation between BMI evolution and 
severe immunodeficiency but only in a long term.  Additionally, high BMI change, alone or in 
combination with high CD4 gain may not reflect optimum adherence to treatment in the context 
of resource limited settings (Messou et al, 2008).  
 
Regarding MCH, in a cohort study with patients who initiated antiretroviral therapy and had 
concurrent HIV/RNA biomarker ≥ 4 months after ART, Lau et al (2010) found that MCH and 
change in MCH were the strongest predictors of HIV/RNA ≥ 500 copies/ml. However, this 
difference with our results could be explained by the fact they only assessed routinely collected 
clinical markers in addition to CD4 and without additional information on adherence (Lau et 
al, 2010). Another study by Bison et al (2008) has suggested that inclusion of adherence data 
is more likely to change the diagnostic value of MCH for detecting viral load suppression or 
treatment failure (Bisson et al, 2008). 
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4.5 Missing ARV visit or medical visit and plasma viral load response 
Our results show that patients who missed two ARV visits within the first 6 months are two 
times more at risk for detectable viral load, holding all other variables constant. This result is 
in line with another study in South Africa and in developed countries. Brennan et al (2010) 
analysed data from 4476 HIV-infected patients initiating ART at Themba Lethu Clinic in 
Johannesburg and found that missing medical or ARV visits was a marker of poorer outcome. 
Specifically, the study showed that HIV-positive patients who missed three or more medical 
ARV visits were more likely to fail to suppress their viral load during the first 6 months. It is 
likely that missing visits is a marker of poorer adherence which potentially could lead to 
treatment failure and drug resistance.  
4.6 Self-reported adherence (SRA) and viral load response 
 
 
- Visual Analogue Scale 
 
Our findings show that over 80% of HIV-infected patients were reported to be highly adherent 
to ART during the first 6 months when adherence was assessed with the Visual Analogue scale, 
but this percentage decreased to nearly 60% at 12 months. Not only that, we additionally found 
that, during the first 6 months, patients identified as adherent with the VAS tool were more 
likely to have a suppressed viral load.  The high percentage of HIV-infected patients classified 
as adherent by VAS is consistent with what has been reported from previous findings 
(Deschamps et al, 2008; Kiwuwa-Muyingo et al, 2012).  
 
The results in our study confirm previous studies that found that self-reported adherence is 
associated with undetectable viral load and better outcome (Raboud et al, 2002; Bandsberg et 
al, 2006). However, our study shows that, when viral load was taken as the gold standard, the 
VAS demonstrated low sensitivity and low positive predictive values while its specificity and 
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negative predictive values were high at 6 and 12 months. Thus, our results imply that, within 
the first 6 months of ART, using VAS to assess adherence in HIV-infected patients will lead 
to nearly 75% of patients with truly detectable viral load being missed and classified as 
negative, added to the fact that when VAS is used as a first screening test, the probability that 
a patient classified as non-adherent having a detectable viral load is only 46%.  The same trend 
was observed at 12 months of ART.  
 
These findings reveal, although self-reported adherence measures can be associated with 
detectable viral load, using VAS as a single tool to assess adherence to ART may have major 
limitations. Our results confirm the limit to validity attributed to the VAS and support other 
findings (Kabore et al, 2015; Chkhartishvili et al, 2014; Berg & Arnsten, 2006) from developed 
and resource limited settings that reported a higher misclassification probability and 
overestimation of adherence with the VAS tool.  
 
The fact that patients who reported adherence with the VAS or other self-reported adherence 
measures were more subject to the issues of recall bias and social desirability can explain this 
overestimation and misclassification when compared to viral load. In the LCM project, patients 
were provided with financial or conditional economic incentives to come to medical visits and 
this situation may have translated to a higher report of adherence level during medical visits. 
Similarly, many studies (Galaraga et al, 2014; Sorensen et al, 2007) have demonstrated that 
economic incentives to be successful at improving patient’s adherence to medical treatment. In 
this context, while not all, some patients may know that if they stop taking their medication, 
they may risk financial constraints and these events were more likely to occur during routine 
medical or ARV visits at TLC. Therefore, our results may not be fully reproducible in routine 
clinical practice where economic incentives are not used.  
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However, some authors (Langebeek et al, 2014; Segeral et al, 2010) have suggested that given 
the complex factors surrounding ARV therapies and adherence, economic incentive and 
remuneration fear may not fully explain the high self-report adherence. Additionally, other 
studies suggest that conditional incentives may only reflect adherence level in the short term 
follow up.  In their meta-analysis that included 15351 HIV-infected patients from 65 countries, 
Langebeek et al (2016) studied the relation between self-report adherence and plasma HIV-
RNA in adult non-pregnant patients on ART. Their results demonstrated that an adherence 
threshold below 95%, social desirability and lack of confidence of the patient may affect the 
accuracy of the relationship between viral load and self-report adherence (Langebeek et al, 
2014) (Segeral et al, 2010).  
 
The issue of reporting bias is known from previous research findings and some authors have 
even suggested the use of anonymous Computer Assisted Interviews (CASI) to avoid face-to-
face interviews  between HIV-infected patients and healthcare workers (Berg & Arnsten, 2006)  
(Arnsten et al, 2001). 
 
- Simplified Medication Adherence Questionnaire 
HIV-infected patients assessed with the SMAQ tool showed high levels of adherence but very 
low sensitivity when compared to viral load as gold standard. Our findings show that the 
diagnostic accuracy of the SMAQ is almost similar of that of the VAS at 6 and 12 months. The 
fact that SMAQ was also a tool based on retrospective questions and was not anonymous, 
suggest that performance could also be affected by the issues of recall bias and social 
desirability. This may explain the similarities of the results between the SMAQ and the VAS.  
Contrary to our findings, the validation study of the SMAQ carried out by Knobel et al (2002) 
in Spain in a large cohort of HIV-infected patients, recorded high levels of diagnostic accuracy 
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for the SMAQ tool. During this validation study, the SMAQ showed 72% sensitivity and 91% 
specificity when compared with the medication-event monitoring (Knobel et al, 2002). Not 
only that, non-adherence assessed by the SMAQ was the only factor associated with a failure 
to suppress viral load after adjusting with other factors (Knobel et al, 2002). The apparent 
discrepancies between our diagnostic accuracy rates for SMAQ adherence may be due to 
different drug in the ARV regimen and the gold standard used during the validation study in 
Spain. In our study, the viral load was considered as the reference standard whereas in the 
validation study by Knobel et al (2002), they used an electronic device and adherence was 
recorded as the number of doses recorded by the electronic system over the total number 
prescribed during the follow-up (Knobel et al, 2002). Additionally, in their study, the HIV-
infected patients in whom adherence was assessed were initiated on a Nelfinavir-based PI 
regimen which is different to NRTI and NNRTI regimens used in standard first-line ART in 
South Africa. 
 
- Multi-method approach  
Our findings showed that during the average period of six months, the multi-method tool which 
combined VAS, PIT and self-report questionnaire into a single adherence measure was not 
more accurate than the simple self-reported adherence such as VAS and SMAQ. In contrast, 
another study from Steel (2007) has shown that the validity of applying a combination of tests 
is higher compared to a single test to assess adherence to antiretroviral treatment (Steel et al, 
2007). This multi-tool approach has also been recommended by WHO since 2003 (WHO, 
2003). In a large evaluation study carried out in South Africa by Steel and colleagues (2002), 
a multi-method approach was demonstrated to be superior to single measures which 
overestimated adherence amongst patients on “d4T-3TC-EFV” regimen. This study also 
demonstrated a strong positive correlation between high viral load and high level of adherence 
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assessed with the multi-method approach. The fact that in our study, HIV-infected patients 
were ART naïve prior to treatment initiation and the fact that we adjusted for other variables 
that might have influenced or confounded the relationship between multi-method approach and 
viral load may explain these differences. Additionally, even though multi-method tool is 
indicated to reduce the error associated with single self-reported measures of adherence, 
evidence is lacking on how to best combine different measures of adherence into a single 
accurate and reliable tool (Berg & Arnst, 2010). 
 
In our study, we used a cut-off of 95% adherence or better as proxy for viral load suppression. 
This cut-off was based from previous studies that found that this level of adherence would at 
least induce 80% of viral load suppression. However, since this level of adherence can be 
sometime very difficult to attain due to different causes that include: lack of social support, 
demographic factors, drug resistance, pharmacokinetic factors and side effects. Additionally, 
some authors (Bangsberg, 2006; Viswanathan et al, 2016)  have suggested that a lower level 
of adherence may be required in order to remove all the barriers and improve access to ART. 
Additionally, it is possible that the advanced pharmacokinetics of new ARV drug and their 
lowered genetic barriers may influence the level of adherence required for viral load 
suppression. Thus, a study by Bangsberg et al (2004) showed that the level of adherence 
required to suppress viral load was lower that usually expected. In a longitudinal cohort study 
amongst 1552 HIV adult persons including men having sex with men and injection drug users, 
Viswanathan and colleagues (2016) showed that at adherence levels between 80 and 84%, the 
odds of viral load suppression were not significantly different than that in patients with ≥ 95% 
adherence levels. Further studies that could confirm this finding in South Africa are needed.  
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4.7 Diagnostic risk score and viral load  
 
We used the modified Poisson Regression models to derive a continuous risk score at two-time 
points: during the first 6 and 12 months on ART. The diagnostic risk score performed well at 
6 months. However, at 12 months, the continuous diagnostic risk score was uninformative and 
performed less than the self-reported adherence measures. The fact that more adherent patients 
at the first 6 months were more likely to survive until 12 months and we measured the 
performance of the 12 month’s risk score with a prevalent cohort and stable patients may 
explain this situation (Miller et al, 2012) . 
 
During the first 6 months, we found that a predictor score including demographic variables, 
laboratory and clinical information follow-up, self-reported adherence and the information on 
missed ARV visits or medical visits performed better than the self-reported adherence 
measures for predicting detectable viral load.  The predictor score at 6 months included age, 
gender, platelet count response, WHO stage, CD4 count response, VAS score and the missing 
ARV or medical visits. The AUC to detect failure to suppress viral load was calculated as 0.63, 
meaning that we should expect that randomly selected  patients with detectable viral load would 
have a higher predicted probability or risk score of about 63% of the time than  randomly 
selected patients without detectable viral load (Hanley & McNeil, 1982). Taken alone, the AUC 
of the 3 self-reported adherences were 0.56, 0.52 and 0.52 respectively for the VAS, SMAQ 
and multiple approach method, meaning that they cannot compare between patients with and 
without detectable viral load, and there is a little increment value gained between these 3 self-
reported adherence measures. We considered two cut-off values for the risk score (risk score ≥ 
5 and risk score ≥ 4) for providing the optimal true positive rate while decreasing the false 
negative rate. For example, the application of the predicted risk probabilities at the cut-off point 
of ≥ 4 (Se 76.4% vs VAS 24.50%, SMAQ 26.5%, multiple-approach method 18.4%) would 
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result in significant decrease of false negative results than the use of the self-reported adherence 
measures.  
 
Additionally, if we consider that missing a patient with detectable viral load is more dangerous 
than incorrect identification of patients with a good adherence to ARV, the cost of false 
negative is more important than the cost of false positive. Therefore, the cut-off (≥ 5 vs < 5) 
although not optimal, seems to be the best to classify HIV-positive patients as adherent and 
non-adherent. The cost of false negative results may include mortality, virologic treatment 
failure and switch to more expensive second line treatment. 
 
Of the 3 self-reported adherence methods, only a VAS < 95% during the first 6 months and 
after adjusting for other variables in the modified Poisson multivariate model, was significantly 
associated with a failure to suppress viral load. The AUC of the VAS at 6 months was only 
0.53.  In their study among HIV-positive patients in Eastern Europe, Chkhartishvili et al (2014) 
used a multivariate modified Poisson regression model to evaluate the measures of 
antiretroviral adherence in HIV-patients in Georgia. In their model, after adjusting for age, 
gender and other adherence measurements (refill adherence, four-day ACTG questionnaire), 
the VAS value < 95% was associated with viral load suppression with AUC being 0.64 and 
0.72 for viral suppression of < 400 copies/ml and < 50 copies/ml respectively (Chkhartishvili 
et al, 2014). However, in their study the self-reported adherence was measured only three 
months after enrollment and they excluded individuals with missing values (Chkhartishvili et 
al,2014). Thus, it is difficult to compare the validity of the results in a long-term period such 
as at 6 or 12 months on ART.  
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Some studies among HIV-positive patients in developed countries have developed risk scores 
derived from combining self-reported adherence measures and laboratory and clinical markers 
in order to predict viral load in patients on ART (Lynen et al, 2009; Segeral et al, 2010 ;Van 
Griensven et al, 2014; Colebunders et al, 2006; Evans et al, 2014). However, most of them 
used more stringent criteria to target virological failure or first line treatment failure instead of 
using the cut-off point of > 400 copies/ml for viral load as we did in thïs study.  In their study 
from Cambodia, Lynen et al (2009) used laboratory data, clinical information and self-reported 
adherence measures (SMAQ and VAS) to develop a scoring system in HIV-patients with 
suspected first line therapy failure and on treatment for at least 12 months. A risk score >2 
including hemoglobin drop >1g/dl, CD4 count response below baseline, 25% drop in CD4 from 
peak, CD4 <100 cells/mm3, VAS < 95% adherence had an optimal combination of sensitivity 
(41.4%) and specificity (92.6%) to target virologic failure which was defined as one viral load 
>1000 copies per milliliter (Lynen al . 2009). Similar to the results of our study, this study in 
Cambodia showed that a VAS value < 95% was predictive of having a viral load >1000 
copies/ml after adjusting with other variables in the multivariate model (Lynen al. 2009). 
Similarly, an algorithm developed in Uganda used a scoring system including CD4 count, 
MCV ≤ 95 fL, percentage adherence ≤ 90%, and clinical information to predict virologic 
failure. A cut-off score of 3 was chosen and resulted in a sensitivity of 40% in the derivation 
population and a PPV of 100% (Colebunders et al, 2006). However, in these two studies, the 
authors did not mention the follow-up period during which the diagnostic risk score may be 
applicable or discriminative.  
 
In our study, we defined and evaluated the diagnostic risk scores for two follow-up periods and 
the fact that our study was prospective with ART-naïve HIV-infected patients strengthens the 
discriminative value of our risk score. Our results implied that, within the first six months, the 
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diagnostic accuracy applied with risk threshold of 4 or 5 can help to identify HIV-infected 
patients for therapeutic group support or viral load testing in a more cost-effective manner. At 
the cut-off score of 5, the risk score for targeted viral load testing at 6 months correctly 
identified 65% (47/72) of patients with a detectable viral load, while reducing viral load test by 
more than 40% and this saved 103 viral loads according to current guidelines. In South Africa, 
Evans et al (2014) used routinely collected electronic health data from ART clinic to identify 
virologic failure defined as 2 consecutive HIV-RNA ≥ 400 copies/ml. The algorithm developed 
by Evans et al (2014) was done in a large retrospective dataset and resulted in more variables 
being included in the final CPS with a combination of age, CD4 count < 100 cells/mm3, WHO 
stage III/IV, albumin < 25 g/dl and laboratory and clinical follow up data. Additionally, they 
found that a score including CD4 criteria identified better patients with treatment failure than 
a score without CD4 criteria and better than WHO immunologic and clinical criteria (Evans et 
al,2014). 
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Table 17 Sensitivities and specificities of different CPS in the literature. 
Reference Outcome Se Sp PPV NPV 
Lynen et al, 2009 Viral load > 1000 copies/ml 41% 92.6% 22.1 96.9 
      
Meya D et al, 2009 Viral load failure < 1000 copies/ml 67% 82% 100% 97% 
      
Keiser et al, 2009 Virologic failure:  12.6% and 48.1% 86.8 and 97.3% 9.5% and 19.0% 98.5% and 95.7% 
 > 10000 & > 500; 2 measurements     
      
Evans et al, 2014 2 consecutives HIV/RNA load > 1000 copies/ml    
Score with CD4 criteria (≥ 4vs.< 
4)  57.1 % 50.5% 27.8% 77.9% 
Score without CD4 criteria (≥ 4 vs.< 4) 40.9% 52.7% 64.0% 50.0% 
      
This CPS (≥ 5 vs. < 5) 
Single elevated viral load > 400 
copies/ml 64% 50% 35.6 % 75% 
Se: sensitivity Sp: Specificity PPV: Positive predictive value NPV: Negative predictive value 
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4.8 Plausible reasons for missingness and impact of the missing data   
 
The exploration of the missingness mechanism prior to the imputation model aimed at seeing 
if the missing data in the predictors or the outcome are predictable from the observed data in 
the LCM dataset. Our analysis shows that the MCAR mechanism seems to be more consistent 
with the observed dataset, meaning that the probability for a missing viral load value was not 
associated with any predictor in the LCM dataset. Similarly, the probability that a value was 
missing for one of the predictors was not related to failing to suppress viral load at 6 or 12 
months. Since the missing data are not related to the values, the observed data in the LCM 
study can be considered as representative of the LCM study population and the occurrence of 
the MCAR mechanism doesn’t cause bias in the analysis (Carpenter and Kenward, 2013). In 
this situation, the result from the complete case analysis reflects the analysis of data which is  
available and doesn’t cause bias except that the sample size is reduced (Donders et al, 2006) 
(Collins et al, 2015). Thus, we can considerer the results from the complete case analysis as 
unbiased estimates and representative of the study population.  
Additionally, the fact that data are MCAR, may explain the reason why the complete case 
analysis and the analysis from the imputed dataset gave different results at 6 and 12 months.  
4.9 Limitations of the study  
 
The results from this study should be considered in light with several limitations. First there 
were many factors that may have affected the viral load that were not available in the LCM 
dataset, such as drug resistance, other co-infection or following immunization. Also, because 
some patients had not undergone a viral load assessment, we used the window period of 6-9 
months and 10-12 months to capture the 6 and 12 month’s viral load respectively. This 
approximation reduced the missing data which may have affected the results. Additionally, the 
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fact that not all patients underwent HIV viral load assays may have led to verification bias and 
biased estimates. 
Secondly, our study only included patients that were initiated at Themba Lethu Clinic and who 
were not referred from another facility. This type of patient selection might have led to highly 
selected patients not representative of patients on ARV treatment in South Africa. Moreover, 
TLC is an HIV specialized center with highly skilled staff and clinical practices in HIV 
treatment that might differ significantly from other health centres in South Africa. Therefore, 
our results may not be generalizable to the overall population. Regarding the diagnostic risk 
score, results from stimulation studies have demonstrated that the statistical power in a 
prediction model is based on the number of event per variables (EVP) and a minimum of 10 
EVP is required for a reliable prediction (Moons et al, 2015; Collins et al, 2015).This rule was 
not respected during the primary data collection at TLC as we had an average of 9 EVP and 4 
EVP for the 6 and 12-month prediction model respectively.  
Fourth, in our study, we used viral load suppression as gold standard to assess adherence to 
antiretroviral therapy because of sample follow up, we could only look at viral load suppression 
defined as a single measure of HIV/RNA ≥ 400 copies/ml.  
Finally, the main limitation is related to the inconvenience of using routine clinical care data 
which resulted in a lot of missing data, some authors suggest that variables with more than 50% 
of missing data should be excluded from the application of the diagnostic model as they may 
be  more difficult to obtain in routine care data (Steyerberg & van Veen, 2007). 
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CHAPTER FIVE - CONCLUSION AND RECOMMENDATIONS 
 
5.1 Introduction  
 
The conclusion and recommendation are based on the results and their discussion in the 
preceding chapter. In this chapter, we also highlight some recommendations and suggest the 
potential areas where further research is needed. 
 
5.2 Conclusion 
 
Adherence to antiretroviral therapy remains a key aspect for the success of the antiretroviral 
programmes. Currently, tremendous efforts are being put into improving adherence to ART in 
patients on first-line regimens in developed and resource-limited settings. However, despite the 
abundant literature, adherence to ART is not easy to monitor and the bias associated with the 
use of self-reported adherence measures has been previously reported. Other measures include 
plasma viral load monitoring, therapeutic drug monitoring, pill count, pharmacy refill data, 
electronic monitoring device (MEMS). However, these methods are costly and difficult to 
implement in resource-limited setting. An accurate and low-cost adherence measure based on 
routine clinical data and laboratory markers available in daily practice may be useful to predict 
viral load and monitor adherence to ART in patients on first line ART. Our study aimed to 
identify the usefulness of a composite marker of poor adherence assessed by failure to achieve 
virologic suppression and defined as a plasma viral load ≥ 400 copies/ml in patients on first-
line ART at Themba Lethu Clinic, in Johannesburg, South Africa 
In this study, the prevalence of patients with a detectable viral load was 30.1% and 28.5% at 6 
and 12 months respectively. By 6 months, the risk factors associated with a detectable viral 
load were having a six months platelet count <100 cells/mm3, a visual analogue scale value < 
95% and “having missed at least one ART or medical visit”. While at 12 months, only variables 
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such as being aged older than 35 years, unemployment and alcohol consumption were related 
to a detectable viral load.  More than 50% of HIV-positive patients were initiated on a TDF-
based regimen but there was no association between the ART-regimen and the viral load. These 
findings confirmed that patients initiating ART are more vulnerable to poorer outcome during 
the first six months on ART, regardless of the first-line regimen they were initiated on. 
Additionally, our findings highlight the importance of better and regular monitoring of the 
antiretroviral drug therapy within this first six months. 
 In the analysis using the case complete analysis, except for platelet count, the changes 
observed in laboratory markers were not associated with a detectable viral load at 6 and 12 
months on highly active antiretroviral treatment (HAART). This may be due to the large 
amount of missing data in the predictors and outcomes and the smaller sample size in our study. 
Our results may also suggest that some changes observed in laboratory markers are mostly 
associated with the long-term prognosis of HIV/AIDS infection rather than being an early 
predictor of the treatment effect.  
Overall, HIV-positive patients reported high-adherence levels at 6 months which decreased 
slightly at 12 months. In contrast, when the self-reported adherence measures were compared 
with viral load, their specific sensitivities were very low, resulting in a higher proportion of 
false negative results. This misclassification may be explained by the overestimation of 
adherence that is associated with the self-report tools and reported in previous studies. As a 
result, this high proportion of false negative test may expose HIV-positive patients to an 
increased risk of virologic and treatment failure and later drug resistance. 
We developed two continuous diagnostic risk scores derived from the Modified Poisson 
regression models at 6 and 12 months. The 6 months diagnostic risk score which combined 
patient demographic characteristics (age, gender), WHO stage, laboratory markers (platelet 
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count, MCV and CD4 count, missing ARVs or medical visit) showed a high discriminative 
value. 
Additionally, there was higher sensitivity, specificity and negative predictive values at two 
different cut-offs (risk score ≥ 5 and risk score ≥ 4) compared with the self-reported adherence 
measures. However, at 12 months, the risk score derived from the modified Poisson regression 
model showed overall lower discriminative value (ROC area of 0.4) and was uninformative 
when compared with self-reported adherence measures. As a result, the high sensitivity and 
specificity of the risk score during the first six months indicates that this method is an important 
tool that can be used to reduce the high proportion of patients falsely classified as adherent by 
the self-reported adherence measures.  
On the other hand, the high predictive value means that it is possible to rule-out poor adherence 
in large numbers of patients, reducing unnecessary stress and burden. Our results indicate that 
if we consider that missing a patient with detectable viral load is more dangerous than incorrect 
identification of patients with good adherence to ARV, the cost of false negatives is more 
important than the cost of false positives. Therefore, the cut-off, although not optimal (≥ 5 vs 
< 5) seems to be the best to classify HIV-positive patients as adherent and non-adherent. The 
cost of false negative results may include mortality, restriction of quality of life, virologic 
treatment failure and therapeutic cost.  
Our findings suggest that during the first six months on ART, a diagnostic risk score tool can 
be used to estimate the probability that an HIV-positive patient has a detectable viral load. HIV-
infected patients with a high-risk score (risk score ≥ 5 or risk score ≥ 4) may be helped to get 
additional support and counselling such as therapy group regimen and information on how to 
take their ARV drugs. In resource-limited settings, the viral load may only be used to confirm 
the diagnosis during the first six months. In this study, the predictors used are readily available 
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in routine care data and the risk score was developed with cut-off values in line with clinical 
practices. Thus, they are easy to adapt in routine clinical care and in daily practice during 
medical visits. 
5.3 Recommendations  
 
 
Following our findings and the comparison with previous research, the following 
recommendations aim to enhance the validity of the diagnostic risk score and its application at 
Themba Lethu Clinic. 
- Include the diagnostic risk score at 6 months in the routine practice at Themba Lethu 
Clinic for assessing its internal validity and its applicability to HIV-infected initiated 
receiving care from this center. 
- The 6 months prediction model should also be externally validated to ensure its external 
applicability to other settings to improve its performance before its use in clinical care. 
Thus, the model can be improved by including new biomarkers or the regression 
coefficient adjusted before its implementation in clinical care. 
- Conduct a more active follow-up of patient’s information on self-reported adherence 
measures and laboratory markers to avoid the occurrence of missing data. 
- Provide adequate training to the health professionals at TLC to ensure that all the 
patient’s clinical information is recorded and completed in the TherapyEdge-HIVTM 
database. 
- There may be other markers of adherence to ARV treatment from routine clinical care 
or laboratory data. Thus, it may be useful to explore their added value in the diagnostic 
risk score at 6 and 12 months. 
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7.5 Appendix E: Characteristics of patients in the Themba Lethu Clinical HIV Cohort and in the 
LCM study. 
 
Characteristics 
Pre-ART (n=8217) 
n (%) 
ART (n=21099) 
n (%) 
LCM cohort 
(n=357) n (%) 
 Gender     
 Female 5222 (63.6%) 13428 (63.6%) 226 (64%) 
 Male  2995 (36.4%) 7671 (36.4%) 127 (36%) 
 Nationality     
 South African  7608 (92.6%) 19195 (91.0%) 301 (85.3%) 
 No South African  609 (7.4%) 1,904 (9.0%) 51 (14.5%) 
 Missing  0 (0%) 2 (0%) 1 (0.2%) 
 Education level     
 No formal education  1151 (14.0%) 634 (3.0%) 13 (3.7%) 
 Primary school  648 (7.9%) 2946 (14.0%) 25 (7.1%) 
 Secondary school  2445 (29.8%) 11320 (53.7%) 257 (72.8%) 
 Tertiary education  160 (2.0%) 744 (3.5%) 15 (15.0%) 
 Missing 3813 (46.3%) 5357 (25.8%) 11 (3.2%) 
 Employment status    
 Unemployed  4434 (54.0%) 11121 (52.7%) 206 (58.4%) 
 Employed 3783 (46.0%) 9978 (47.3%) 147 (41.6%) 
 Missing 0 (0%) 2 (0%) 0 (0%) 
Characteristics at ART 
Initiation     
 Age (median IQR)  36 (30.8 - 42.6) 37 (21.0 - 57.0) 
 BMI (Kg/m2)    
 < 18.5  3140 (14.9%) 22 (6.2%) 
 18.5 – 24.9  9025 (42.8%) 192 (54.4%) 
  25 – 29.9  2804 (13.3%) 74 (20.9%) 
 ≥ 30  1302 (6.2%) 51 (14.4%) 
 Missing   4830 (22.9%) 14 (3.9%) 
 Median (IQR)  221.7 (19.1 - 25) 23.5 (16.3 - 43.8) 
 CD4 count category (cells/mm3)    
 < 50  5224 (24.8%) 46 (13.0%) 
 50 – 100  3231 (15.3%) 44 (12.5%) 
 100 – 200  5725 (27.1%) 89 (25.3%) 
 200 – 350  2359 (11.2%) 143 (40.6%) 
 > 350  705 (3.3%) 30 (8.5%) 
 Missing   3857 (18.3%) 1 (0.3%) 
 Median (IQR)  103 (39 - 178) 196 (98 - 268.5) 
 Haemoglobin (mmol/L)    
 Median (IQR)  11.6 (10.0 - 13.1) 12.3 (11.0 - 13.5) 
 TB    
 Yes  2519 (11.9%) 36 (10.2%) 
 No  8582 (88.1%) 313 (88.7%) 
 Missing  0 (0%) 4 (1.2%) 
 HIV viral load (copies/ml)    
 ≤ 1 00,000  3,197 (7.2%) NA 
 > 1 00,000  1,527 (15.2%)  
 Missing   16,377 (77.6%)  
